

Curriculum Vitae

Mehran Karimi


June 2020



Contents

Education History:.....	2
Professional History:.....	2
Honors:	3
Experience:.....	4
Books:	5
Certifications:	5
Membership:	5
Presentations	6
Publications (Current h-index 41):.....	35

Citation indices	All	Since 2011
Citations	6782	5604
h-index	41	28
i10-index	294	171



Personal History

Address: **M. Karimi, MD, Professor of Pediatric Hematology-Oncology**
1-Hematology Research Center,
Pediatric Oncology Department, Amir Hospital, Shiraz, Iran.
2-14249 Carlow Run, Carmel IN 46074, USA
E-mail: mkarimi820@gmail.com

Education History:

2003	Fellowship of Thrombosis, Hemostasis & Thrombosis Research Center Milan Italy
2001	Training of Haemophilia, Milan Haemophilia Center, Milan – Italy
1999	Subspecialist (Board certification) in Ped. Hematology/Oncology, Iran
1996 - 1997	Training of Bone Marrow Transplantation, Saint James' Hospital. Leads, United Kingdom
1994 - 1996	Fellowship in Pediatric Hematology – Oncology, School of Medicine, Ahvaz University of Medical Sciences, Ahvaz – Iran
1991 – 1993	Residency in Pediatrics, Pediatric Specialty, School of Medicine, Shiraz University of Medical Science, Shiraz – Iran
1983 - 1990	Medical School (MD), School of Medicine, Shiraz University of Medical Sciences, Shiraz – Iran
1979 – 1983	High school, Razi High School, Shiraz – Iran

Professional History:

2016-2017	Physician researcher (research scientist) at IHTC, Indiana, USA
2015-present	Editorial Board of International Journal of Hematology and Therapy
2014-present	Editorial Board Member of Thalassemia Reports journal
2012-present	Consultant Pediatric Hematology-Oncology, Iranian Hospital, Dubai, UAE
2012-present	Editorial board of EndoThal Journal

- 2012** **Lead Guest Editor of Anemia Journal**
- 2012-2015** **Editorial board of International Journal of Biomedical Science**
- 2011-present** **Editorial board of World Journal of Clinical Pediatrics**
- 2009-2013** **Editorial board of World journal of Radiology**
- 2009-2016** **Member of pediatric hematolgy-oncology board exam**
- 2006-2015** **Medical Director of Shiraz Hematology Research Center, Shiraz, Iran**
- 2004-present** **Professor of Pediatric Hematology-Oncology, Hematology research center, School of Medicine, Shiraz University of Medical Sciences, Shiraz – Iran**
- 2004-present** **Invited speaker at many National and International guest speakers meetings**
- 2004-present** **Peer reviewer of European journal of Hematology, Annals of Hematology, Journal of Thrombosis & Haemostasis, Hemoglobin, Hemophilia, Internationa journal of preventive Medicine, Iranian Journal of Pediatrics, Iranian Red Crescent Medical Journal and Hematology journals**
- 2004-2015** **Iranian Board of Pediatrics Hematology – Oncology, Iran**
- 2004-2009** **Editorial board of Iranian Journal of Medical Sciences**
- 2000** **Associate Professor of Pediatric Hematology, Hematology research center, School of Medicine, Shiraz University of Medical Sciences, Shiraz – Iran**
- 1998-2016** **Advisor and supervisor of more than 100 thesis of medical students, residents, fellowship and PhD**
- 1996** **Iranian Board of Pediatrics, Iran**
- 1993** **Assistant Professor of Pediatric Hematology – Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz – Iran**

Honors:

- 2014-2015** **Appriication letter from Shiraz University of Medical Sciences due to remarkable reasech activities in the field of hematolgy-oncology, Iran**
- 2014** **15th Abu Reyhan Biruni Research Festival Award, Tehran, Iran**
- 2011** **Appreciation letter (plate)from TIF (Thlassemia International Federation) because of performing significant scientific activities in Thalassemia**
- 2010** **Appreciation letter (plate) from ISTH (Intenational Society of Thrombosis and Hemostasis) committee because of having well organized and scientific congress as president in Iran**
- 2008** **Razi Festival award as a best researcher in Iran**

- 2003-2013 Best Researcher in Shiraz University of Medical Sciences, Shiraz, Iran**
- 2003 Razi Festival award as a best researcher in Iran**

Experience:

- 2010 Holding up International congress of Thrombosis & Haemostasis as president**
- 2008 Approved Peditaric Oncology and hematology wards to get fellowship**
- 2006 Founder of Thrombosis & Hemostasis Research Center**
- 2002 Establish PND & modify prenatal screening including inaugural of α thalassemia genetic analysis as well as β genetic analysis in suspected cases**
- 2002-2013 TV Releases & Interviews in Anemia, Thalassemia, Haemophilia and Cancer in SHOMA TV and FARS TV, Iran**
- 2000 Founder of 18 thalassemia wards in 18 local cities hospitals affiliated with Shiraz University of Medical Sciences in Fars Province, Iran**

International

Grants:

- 2015-2018 Forma02, 04 study (Mutinational study, clinical response of a new plasma drived Fibrinogen concentrate in Afibrinogenemia patitients). Local principal investigator, **\$50000 grant****
- 2010-2014 SIPPET Study (Comparing incidence of Inhibitor development in untreated Hemophilia A patients bewwen plasma drived and recombinant). Local principle investigator, **\$220000 grant****
- 2012-2018 Winter Study (Von willbrand disease registry & inhibitor development, A 5-year International Registries and Prospective Study on VWD Type 3), Local principal investigator, **\$10000 grant****
- 2012-2014 Forma-1 Study (Multinational study of PK assay of a new Fibrinogen concentrate in Afibrinogenemia patients). Local principal investigator, **\$27000 grant****
- 2012-2015 Smart Study (Immunogenicity evaluation of RT rFVIIa in hemophilia A patients with high titer inhibitor). Principal investigator, **\$10000 grant****
- 2006-2007 STER Study (Factor VII registery in patients with congenital FVII deficiency). Principle investigator, **\$12000 grant****
- 2009-2010 FX Study (Clinical and PK evaluation of a new FX concentrate in**

2009-2010 congenital FX deficiency). Principal investigator, **\$20000 grant**
Optimal care study (Clinical and paraclinical evaluation of Thalassemia intermediate Patients), Local principal investigator, **\$7500 grant**

Books:

- 2014** Care during and after pregnancy in women with anemia and thalassemia
- 2013** Interpretation of complete blood count and review of anemia
- 2011** How could we improve the quality of life of leukemic children and their families?
- 2008** Comprehensive management for Hemophilia in Iran
- 2006** Comprehensive health Services in thalassemia patients
- 2006** Translation of Guidelines for the Management of Hemophilia by WFH

Certifications:

- 2016** CITI Good clinical practice (GCP) course from USA
- 2016** Physicians- Basic/ Refresher course from USA
- 2016** NIH Web-b training course: Protecting Human Research Participants
- 2009-2013** Consultant hematology-oncology on TV, Iran
- 2003** Thrombophilia fellowship training
- 2001** Haemophilia Fellowship Training
- 1997** Bone Marrow Transplantation Training

Membership:

- 2012-present** Member of ASH (American Society Hematology)
- 2010-present** Member of international Network on Endocrine complications in thalassemia (I-CET)
- 2003** Member of ISTH (International Society Thrombosis and Hemostasis)
- 2005-present** Member of thalassemia and Hemophilia committee in Ministry of Health, Iran
- 2008-present** Member of ISTH
- 2000** Associate Member, Thalassemia International Federation (TIF)

2003-2016	Member of National foundation of the elite
2008-present	Advisory Board Meeting on Menorrhagia and other Gynecological problems in women affected by bleeding disorders
2000-present	Iranian Pediatric Hematology-Oncology Society
2000-present	MAHAK (pediatric oncology charity)
1999-2012	Director of Fars Hemophilia Society, Iran
1998-present	Fars Oncology and Thalassemia Control Committee, Iran
1998-present	Director of Fars Thalassemia Society, Iran
1997-present	Director of Fars Iron Deficiency Committee

Presentations

1. Maggio A, Vitrano A, Meloni A, Pollina WA, Karimi M. et al. Development of a Severity Score System for Thalassemia Syndromes Presentation. December 8, 2019, ASH 2019; Dec 7-10, Orlando, USA.
2. Karimi M, Zekavat OR, Shakibazad N, Haghpanah S, et al. Study of the Serum Immunoglobulin and Cell- mediated Immunity in Patients with Congenital Severe Hemophilia. ISTH 2019 July 6 – 10, Melbourne, Australia.
3. Karimi M, Shahsavani A, Ayatollahi A, Haghpanah S, et al. Interim analysis of effectiveness of intraarticular injection of mononuclear stem cells in hemophilia patients with joint arthropathy: two case reports. ISTH 2019 July 6 – 10, Melbourne, Australia.
4. Peyvandi F, Schwartz B, Solomon C, Karimi M. et al. Results from a Phase 3 Study of On- demand Treatment with Fibrinogen Concentrate for Acute Bleeding and Surgical Prophylaxis in Patients with Congenital Fibrinogen Deficiency. ISTH 2019 July 6 – 10, Melbourne, Australia.
5. Federici A.B., Peyvandi F, Badiee Z, Karimi M, et al. Annual Bleeding Rates with Efficacy/Safety of the VWF Concentrates used on Demand or under Secondary Long- term Prophylaxis in a Large Cohort of Centrally Confirmed VWD3 Patients: Results of 24- month Prospective Observation in 169 Cases Enrolled into the 3Winters- Ips. ISTH 2019 July 6 – 10, Melbourne, Australia.
6. Karimi M, Zarei T, Haghpanah S, Azarkeivan, Kattamis C, et al. Evaluation of Endocrine Complications in Beta-Thalassemia Intermedia Patients: A Cross Sectional Multi-Center Study. 60th Annual Meeting and Exposition ASH 2018; Dec 1-4, San Diego, USA.

7. Baronciani L, Peyvandi F, Goodeve A, Karimi M. et al. Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease. 60th Annual Meeting and Exposition ASH 2018; Dec 1-4, San Diego, USA.
8. Tosetto A, Badiee Z, Baghaipour MR, Baronciani, L, Karimi M. et al. Clustering of Bleeding Symptoms in Patients Previously Diagnosed as Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Ips Project). 60th Annual Meeting and Exposition ASH 2018; Dec 1-4, San Diego, USA.
9. Peyvandi F, Bucciarelli P, Valsecchi C, Karimi M., et al. Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia a in the Sippet Cohort Study. 60th Annual Meeting and Exposition ASH 2018; Dec 1-4, San Diego, USA.
10. Federici A, Badiee Z, Baghaipour MR, ..., Karimi M, et al. Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project. 60th Annual Meeting and Exposition ASH 2018; Dec 1-4, San Diego, USA.
11. Naderi M., Cohan N, Miri-Aliabad G, Karimi M. Clinical Presentations and Diagnostic Algorithm of Neonatal FXIII-deficiency. ISTH SCC . Dublin, Ireland. July 18 – 21, 2018.
12. Naderi M., Karimi M, Haghpanah S, Miri-Aliabad G, et al. A Cohort Study on Women with Congenital Factor XIII Deficiency in Iran. ISTH SCC . Dublin, Ireland. July 18 – 21, 2018.
13. Karimi M, Farjami A, Hagpanah S, Parand S. Evaluation of Morbidity and Mortality among Patients with Hereditary Bleeding Disorders in Southern Iran. ISTH SCC . Dublin, Ireland. July 18 – 21, 2018.
14. Karimi M, Haghpanah S, Zarei T, Eshgi P, et al. Efficacy and safety of resveratrol, an oral hbf augmenting agent, in patients with beta thalassemia intermedia.23th congress of EHA. 14-17 June 2018. Stockholm, Sweden.
15. Karimi P, Haghpanah S, Bazrafshan A, Karimi M, et al. Clinical outcome of dental surgery in hemophilia patients: Treatment approach in a large referral center. WFH 2018, 20-24 May. Glasgow, Scotland.
16. Karimi M, Ross C, De Angulo GR, et al. Treatment of acute bleeding in adolescent patients with congenital afibrinogenemia: Pharmacokinetics and efficacy of a new fibrinogen concentrate. WFH 2018, 20-24 May. Glasgow, Scotland.
17. Karimi M, Ross C, De Angulo GR, Schwartz BA, et al. Treating acute bleeding in adolescent patients with congenital fibrinogen deficiency: pharmacokinetics and efficacy of a new fibrinogen concentrate. EAHAD 2018; 7 – 9 February , Madrid, Spain.

18. Naderi M, Haghpanah S, Miri-Aliabad G, Tavosi H, Karimi M. A Large Case Series on Surgical Outcomes in Congenital FXIII Deficiency Patients in Iran. 59th Annual Meeting and Exposition ASH 2017; Dec 9-12, Atlanta, USA.
19. Karimi M, Nasirabadi Sh. CRISPR/CAS9 Based Genome Editing of Sickle Cell Mutation in Human Hematopoietic Stem/Progenitor Cells. 14th International Conference on Thalassaemia & Haemoglobinopathies & 16th TIF International Conference for Patients & Parents. November 17-19 2017. Greece.
20. Karimi M, Amirmoezi F, Haghpanah S, Ostad S, et al. Correlation of serum ferritin levels with hepatic MRI T2 and liver iron concentration in nontransfusion beta-thalassemia intermediate patients: A contemporary issue. 14th International Conference on Thalassaemia & Haemoglobinopathies & 16th TIF International Conference for Patients & Parents. November 17-19 2017. Greece.
21. Karimi M, Haghpanah S, Zahedi Z, et al. Frequency of silent Brain lesions and aspirin protection evaluation over three years follow up in thalassemia patients. 14th International Conference on Thalassaemia & Haemoglobinopathies & 16th TIF International Conference for Patients & Parents. November 17-19 2017. Greece.
22. Zahedi Z, Kandi M, Karimi M. The use of mobile applications for distance learning in patients with Beta Thalassemia. 14th International Conference on Thalassaemia & Haemoglobinopathies & 16th TIF International Conference for Patients & Parents. November 17-19 2017. Greece.
23. Karimi M, Haghpanah S, vahdati S. Comparison of Quality of Life in Patients With β -Thalassemia Intermedia And β -Thalassemia Major In Southern Iran. 14th International Conference on Thalassaemia & Haemoglobinopathies & 16th TIF International Conference for Patients & Parents. November 17-19 2017. Greece.
24. Karimi M, Cohan N. Quality of Life: Transfusion dependant Thalassemia Vs Non-transfusion Dependant thalassemia. 14th International Conference on Thalassaemia & Haemoglobinopathies & 16th TIF International Conference for Patients & Parents. November 17-19 2017. Greece.
25. Karimi M. Heridity Bleeding disorders in Neonates. Neonatal Hematology congress, SEPTEMBER 13-15, 2017. Tehran, Iran.
26. Spena S, Garagiola I, ..., Karimi M, et al. Mutational Repertoire in the SIPPET Cohort and Prediction of FVIII Inhibitor Risk. XXVI ISTH Congress, JULY 8-13, 2017. Berlin, Germany.
27. Ross C, Madan B, Karimi M, et al. On-demand Treatment with Fibrinogen Concentrate in Acute Bleeding and for Surgery in Patients with Congenital Fibrinogen Deficiency. XXVI ISTH Congress, JULY 8-13, 2017. Berlin, Germany.

28. Bordbar M, Karimi M, et al. Congenital Hypoprothrombinemia Presenting in the Neonatal Period: Report of 2 Cases in South of Iran. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
29. Ulrich B, Schneppenheim S, Badiee Z, ..., Karimi M, et al. Von Willebrand Factor Antigen Levels in 255 Patients Previously Diagnosed as VWD Type 3 from the Iranian Republic and Nine European Countries (3WINTERS-IPS Study). XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
30. Cannavò A, Spena S, ..., Karimi M, et al. The Influence of F8 Mutation and Thrombophilic Genetic Markers on Bleeding Phenotype of Patients Affected with Severe Hemophilia A in the SIPPEL Cohort. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
31. Shahani T, Pirdel Z, ..., Karimi M, et al. Desmopressin Administration in a Splenectomised Hemophilia A Patient Does Not Affect FVIII, VWF and tPA Plasma Levels: An Evidence for an Indirect Effect of DDAVP. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
32. Tosetto A, Badiee Z, ..., Karimi M, et al. Bleeding Symptoms in Patients Previously Diagnosed as Type 3 von Willebrand Disease: Results from a Multicenter, Multinational Cross-sectional Study. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
33. Goudemand J, Caron C, ..., Karimi M, et al. Comparison of Three Different Factor VIII Assays in 154 Patients with Type 3 von Willebrand Disease: Results from the 3WINTERS-IPS Cohort. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
34. Peyvandi F, Cannavò A, ..., Karimi M, et al. Risk Differential in Inhibitor Development in the First Days of Treatment by Product Class: A SIPPEL Analysis. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
35. Karimi M, Ross C, et al. Pharmacokinetics of Fibrinogen Concentrate and Efficacy in Treating Acute Bleeding in Children and Adolescent Patients with Congenital Fibrinogen Deficiency. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
36. Tahmasbi L, Karimi M, et al. Plasma Platelets Microparticles Evaluation in Thrombotic Thrombocytopenic Purpura. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
37. Baronciani L, Peyvandi F, ..., Karimi M, et al. Profile of Mutations Identified in the 3WINTERS-IPS Project on Iranian Patients with Previously Diagnosed Type 3 von Willebrand Disease. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
38. Nakar C, Hardesty B, Karimi M, et al. Spinal & Cranial Neurosurgical Procedures in Patients with Hemophilia. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
39. Budde U, Schneppenheim S, ..., Karimi M, et al. Von Willebrand Factor Multimer Analysis in 255 Patients Previously Diagnosed as VWD Type 3 from the Iranian Republic and Nine European Countries (3WINTERS-IPS Study). XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.

40. Karimi M, Bordbar M, et al. Successful delivery in an afibrinogenemia patient after three abortions: a case report and review of literature. XXVI ISTH Congress, JULY 8-13, 2017.Berlin, Germany.
41. Amid A, Karimi M, et al. Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinental Collaborative Study. 58th ASH Annual Meeting abstract, Vol. 128, Issue 22, 1 Dec 2016. San Diego, CA, USA.
42. Shahriari M, Karimi M. Are Bleeding Scores Predicting Severity and Outcome in Hemophilia and Rare Bleeding Disorders? 58th ASH Annual Meeting abstract, Vol. 128, Issue 22, 1 Dec 2016. San Diego, CA, USA.
43. Naderi M, Karimi M, et al. A Large-Scale Prospective Cohort Study on Factor XIII Deficiency in Southeast of Iran. 58th ASH Annual Meeting abstract, Vol. 128, Issue 22, 1 Dec 2016. San Diego, CA, USA.
44. Schwartz BA, Karimi M, et al. Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency. 58th ASH Annual Meeting abstract, Vol. 128, Issue 22, 1 Dec 2016. San Diego, CA, USA.
45. Karimi M, Avazpour A, Haghpanah S. Evaluation of proteinuria in β-thalassemia major patients with and without diabetes mellitus taking deferasirox. EHA 21th congress. 9-12 June 2016, Denmark
46. Karimi M , Eshghi P, Meshksar A , Safarpour MM, Haghpanah S, et al. Modified primary prophylaxis in previously untreated patients with severe hemophilia A in Iran.WFH 24-28 July 2016, Orlando, USA
47. Karimi M , Safarpour MM, Haghpanah S, et al. Phenotype Report on Patients with Congenital Factor V Deficiency in Southern Iran.WFH 24-28 July 2016, Orlando, USA.
48. Karimi M, Barati Shourijeh MR, Haghpanah S, et al. Safety Of Defroxsirox (Exjade) In Beta Thalassemia Patients With Serum Ferritin Less Than 1000. 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies. 11 - 12 November 2016 . Amman, Jordan
49. Karimi M, Zarei T, Haghpanah S, Parand S , et al. Evaluation of bone mineral density in patients with hemoglobin h disease. 2nd MEGMA Conference on Thalassaemia and Other Haemoglobinopathies. 11 - 12 November 2016 . Amman, Jordan
50. Karimi M, Mohtadi H, Haghpanah S, et al. Quality of Life in Children with Rare Bleeding Disorders. 57th ASH Annual Meeting. December 3-6, 2015, Orlando, FL, USA.
51. Peyvandi F, Mannucci P, Karimi M, et al. Source of Factor VIII Replacement (plasmatic or recombinant) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with

- Severe Hemophilia a: The Multicenter Randomized Sippet Study. 57th ASH Annual Meeting abstract. December 3-6, 2015, Orlando, FL, USA.
52. Karimi M. Overview of current clinical practice. Novo Nordisk International FXIII Expert Panel Meeting 2015. 16- 17 November 2015. Budapest, Hungary.
53. Karimi M. Management of rare blood disorders – an overview. Business Area Near East (BANE) Haemostasis Advisory Board. 10 November 2015. Istanbul, Turkey.
54. Karimi M. Management of severe congenital protein C deficiency. Protein C deficiency Symposium. 30th October 2015, Istanbul, Turkey.
55. Karimi M. The problem of substandard medicines in the MENA Region: a Physician perspective. MENA Patient Forum on the Quality of Medicines. Novartis Oncology EGM. 10-11 Th October 2015 Dubai, UAE.
56. Karimi M. Tackling the problem of substandard medicines in the Region: securing a voice for patients. MENA Patient Forum on the Quality of Medicines. Novartis Oncology EGM. 10-11 Th October 2015 Dubai, UAE.
57. Karimi M. Silent cerebral ischaemia in TDT-patients. 2nd Pan-Asian Conference. 26-27 Sep 2015 Hanoi, Vietnam.
58. Zareifar S, Bordbar MR, Karimi M, Et al. Lock therapy in children patients with hematologic malignancies. International congress of challenges in pediatric hematology and oncology. IJBC. 16-18 Sep 2015, Tehran, Iran.
59. Zareifar S, Bordbar MR, Karimi M, Et al. What is strategy for Antracyclin leukemic patients in acute leukemia? International congress of challenges in pediatric hematology and oncology. IJBC. 16-18 Sep 2015, Tehran, Iran.
60. Shariari M, Karimi M, Et al. Sever Hemophilia A in a girl infant with with mosaic Turner syndrome and PHPV. International congress of challenges in pediatric hematology and oncology. IJBC. 16-18 Sep 2015, Tehran, Iran.
61. Karimi M. The role of the center in offering optimal care for patients: the holistic approach. 2nd Iraqi Thalassemia Forum .27 th& 28thAugust 2015 Beirut , Lebanon.
62. Karimi M. Management of the difficult patient. 2nd Iraqi Thalassemia Forum .27th& 28thAugust 2015 Beirut, Lebanon.
63. Karimi M. Quality, access and safety of Generic drugs in the region. The Use of Generic Iron chelators in Thalassaemia: Middle East and North Africa Region. Beirut, Lebanon. 29 July 2015.
64. Karimi M, Safarpour MM, Haghpanah S, Gerdabi J and Ardestiri R. Genotype and phenotype report on patients with congenital fibrinogen deficiency in south of Iran. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH). Toronto, Canada, June 20–25, 2015.

65. Schwartz B, Rangarajan S, Karimi M, et al. Pharmacokinetic (PK) comparison of two fibrinogenconcentrates for the treatment of congenital fibrinogen deficiency. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH) June 20–25, Toronto Canada, 2015.
66. Federici AB, on behalf of 3Winters-Ips Investigators, Peyvandi F, Karimi M, et al. New insights into type 3 von Willebrand disease: the type 3 von Willebrand disease international registriesand inhibitor prospective study (3WINTERS-IPS) project update. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH) June 20–25, Toronto Canada, 2015.
67. Peyvandi F, Mannucci PM, Garagiola I, Karimi M, et al. Inhibitor development in relation to treatment duration in severe hemophilia A in previously untreated patients: results from the snippet trial. XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH) June 20–25, Toronto, Canada, 2015.
68. Karimi M, Eshghi P, Haghpanah S, Zahedi Z, et al. Efficacy and Safety of Prophylaxis in Previously Untreated Patients with Severe Hemophilia A in Iran. 20 Congress of EHA, Vienna, Austria, 11-15 June 2015.
69. Karimi M. Role of Fibrinogen in Perioperative bleeding management. 4th workshop v-WD, haemophilia and rare blleding disorders. 27-28 My 2015. Istanbul, Turkey.
70. Karimi M. Role of HMW multimers and ratio of Factor VIII/VWF in different factor concentrates. . 27-28 My 2015. Istanbul, Turkey.
71. Karimi M. General Overview to Rare Bleeding Disorders and its management. Business Area Near East Haemophilia Academy. 19-20 Feb 2015. Istanbul, Turkey.
72. Karimi M. Recombinant versus plasma-derived factors in comprehensive haemophilia management. 19-20 Feb 2015. Istanbul, Turkey.
73. Karimi M. Acquired Hemophilia. Business Area Near East Haemophilia Academy. 19-20 Feb 2015. Istanbul, Turkey.
74. Karimi M, Tavoosi, H, Haghpanah S, et al. Efficacy and safety of FEIBA prophylaxis evaluation in young patients with hemophilia and high titer inhibitor. EAHAD. 11-13 Feb 2015, Finland.
75. Karimi M. Testicular microlithiasis in patients with thalassemia. IV Pan Arab Hematology Association Congress. February 06, 2015 Abu Dhabi.
76. 3. Karimi M. Osteopenia/osteoporosis in thalassemia intermedia. IV Pan Arab Hematology Association Congress. February 06, 2015 Abu Dhabi.
77. Karimi M. Established and emerging management options in NTDT. Thalassaemia Masterclass'14. January 31, Johannesburg, South Africa.
78. Karimi M. What is NTDT? Thalassaemia Masterclass'14. January 31, Johannesburg, South Africa.

79. Karimi M. Presentation of most prevalent complication in SA. Thalassaemia Masterclass'14. January 31, Johannesburg, South Africa.
80. Karimi M. Personalizing treatment by liver and cardiac iron profile. Thalassaemia Masterclass'14. January 31, Johannesburg, South Africa.
81. Karimi M. NTDT diagnosis & complications. UAE Hematology Frontiers. 23rd Jan 2015. Dubai.
82. Karimi M, Tasbihi M, Pishadad P, Haghpanah S, et al. A Comparison between MRI, Sonography and FISH Methods in Diagnosis, Evaluation and Classification of Arthropathy in Severe Haemophilia A and B. 56th ASH Annual Meeting. December 6-9, 2014. San Francisco, CA, USA.
83. Karimi M, Haghpanah S, Bazrafshan A, et al. Evaluation of thrombin generation assay in patients with hemophilia. 56th ASH Annual Meeting. December 6-9, 2014. San Francisco, CA, USA.
84. Schwartz B, Rangarajan S, Karimi M, et al. Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency. 56th ASH Annual Meeting. December 6-9, 2014. San Francisco, CA, USA.
85. Naderi M, Dorgalaleh a, Karimi M, et al. Long Term succesfull Prophylaxis in 190 Patients with Severe Congenital Factor XIII Deficiency, a Four Years Experience. 56th ASH Annual Meeting. December 6-9, 2014. San Francisco, CA, USA.
86. Naderi M, Dorgalaleh a, Karimi M, et al. Clinical Manifestations and Bleeding Episodes Among Heterozygote Individuals of Factor XIII Deficiency , a Short Term Prospective Study. 56th ASH Annual Meeting. December 6-9, 2014. San Francisco, CA, USA.
87. Faranoush M, Abolghassemi H, Toogeh Gh, Karimi M, et al. 56th ASH Annual Meeting. December 6-9, 2014. San Francisco, CA, USA.
88. Karimi M. Cardiac profiles of Iron chelation regimens: oral vs injection. Iranian Thalassemia educational meeting (Switching from Injection to Oral), December 25. 2014
89. Karimi M. TIF guideline, Iranian experience of Oral VS injection. Iranian Thalassemia educational meeting (Switching from Injection to Oral), December 25. 2014
90. Karimi M. Recombinant vs plasma-derived factors in CH management. Business Area near East (BANE) Haemostasis Advisory Board 20 November 2014. Istanbul, Turkey.
91. Karimi M. Drug quality in clinical practice. The Iraqi Thalassemia Forum: Towards Advancing Care and Improving Outcome. Grand Hyatt Hotel, Istanbul, Turkey – November 24th & 25th, 2014.
92. Karimi M. Iron chelation in thalassemia. 1st Gp/Nurse + Summit: what we know & what we learn. 17 &18 December 2014, Tehran, Iran.
93. Karimi M. Inhibitor screening program in Iran. Expert Panel Meeting.2014 10–11 October. London, UK.

94. Karimi M. Iron Overload Management in Thalassemia. Iron chelation therapy. 2014 22. Aug. Vietnam
95. Karimi M. Talassemia Intermedia (NTDT) Overview. Thal.Masterclass. 2014 May. Jakarta, Indonesia
96. Karimi M, Khavari M, Zarei T, Haghpanah S, et al. Association of OR51B2 sequence variations with response to hydroxyurea therapy in Iranian patients affected with beta-thalassemia intermedia. EHA 2014, Milan, Itlay.
97. Karimi M, Zarei T, Haghpanah S, et al. Relationship between BCL11A sequence variations and response to hydroxyurea therapy in Iranian beta-thalassemia intermedia patients. EHA 2014, Milan, Itlay.
98. Karimi M. At the crossroads: How to optimize patient outcomes. EHA 2014 Satellite Symposium. Milan, Itlay.
99. Karimi M, Farjami A, Haghpanah S, et al. Prevalence of morbidity and mortality among patients with hereditary bleeding disorders in southern Iran: A 15 year's experience. WFH May 2014. Melbourne, Australia.
100. Karimi M, Amoozgar H, et al. Evaluation of heart function in patients with hemophilia. WFH May 2014. Melbourne, Australia.
101. Zahedi Z, Karimi M, et al. Critical accepts of hemophilia in Iran: A quick review. WFH May 2014. Melbourne, Australia.
102. Naderi M, Karimi M, et al. Long term two central follow up study on a large group of patients with congenital factor XIII deficiency treated prophylactically with Fibrogammin P. WFH May 2014. Melbourne, Australia.
103. Karimi M. Thalassemia overview. Thalassemia Nurses of School. May 2014. Tehran, Iran.
104. Karimi M. Blood transfusion, complications and treatment. Thalassemia Nurses of School. May 2014. Tehran, Iran.
105. Karimi M, Zahedi Z. Nuse care communicatiuon skill. Thalassemia Nurses of School. May 2014. Tehran, Iran.
106. Karimi M. Clinical experiences with original drug compared to copy frug in Iran. Future Implications of using Substandard Drugs. 19th April, Dubai, UAE.
107. Karimi M, Zahedi Z, Haghpanah S, et al. Evaluation Of Knowledge Of Patients With Hemophilia Regarding Their Disease And Treatment In Iran. European Association for Haemophilia and Allied Disorders (EAHAD). Feb.2014. Brussels, Belgium.
108. Naderi M, Karimi M, et al. Severity of clinical manifestations based on plasms factor activity in rare bleeding disorder. European Association for Haemophilia and Allied Disorders (EAHAD). Feb.2014. Brussels, Belgium.

109. Karimi M. HBF induction. 8 Th Congress of Iranian Pediatric Hematology & Oncology Society. Bandarabbas, Feb 2014, Iran.
110. Zahedi Z, Karimi M, et al. Critical Accepts of Hemophilia in Iranian, A quick review. 8 Th Congress of Iranian Pediatric Hematology & Oncology Society. Bandarabbas, Feb 2014, Iran.
111. Zahedi Z, Karimi M, et al. A Glance on Treatment Process and Side effects of Hepatitis C in Hemophiliacs in South of Iran. 8 Th Congress of Iranian Pediatric Hematology & Oncology Society. Bandarabbas, Feb 2014, Iran.
112. Abdolkarimi, Karimi M, et al. Prevention from chemotherapy medication errors. . 8 Th Congress of Iranian Pediatric Hematology & Oncology Society. Bandarabbas, Feb 2014, Iran.
113. Karimi M. Thromboprophylaxis. Von Willebrand Disease, Hemophilia, and Rare Bleeding Disorders. Intercontinental Jan2014, Kish.
114. Karimi M. vWD, Surgery. Von Willebrand Disease, Hemophilia, and Rare Bleeding Disorders. Jan2014, Kish
115. Karimi M. Accquired VWD. Von Willebrand Disease, Hemophilia, and Rare Bleeding Disorders. Jan2014, Kish
116. Karimi M. Factor X Deficiency current option for treatment. Von Willebrand Disease, Hemophilia, and Rare Bleeding Disorders. Jan2014, Kish
117. Naderi M, Dorgalaleh A, Alizadeh Sh, Karimi M, et al. Molecular Analysis of the Largest Group of Patients with Factor XIII Deficiency in Southeast of Iran. 55th ASH Annual Meeting and Exposition. Dec. 2013, New Orleans, LA.
118. Naderi M, Dorgalaleh A, Alizadeh Sh, Karimi M, et al. The PAI-I Gene 4G/5G Polymorphism and Central Nervous System Bleeding In Factor XIII Deficiency. 55th ASH Annual Meeting and Exposition. Dec. 2013, New Orleans, LA.
119. Karimi M. Best practices registry experience from Iran. Novo Nordisk Haemostasis Advisory Board Meeting. Nov. 2013 Istanbul, Turkey.
120. Karimi M, Zarei T, Haghpanah S. Compliance with Deferasirox (Exjade®) compared to Deferoxamine in patients with transfusion dependent B-thalassemia. 13th International conference on thalassemia and Hemoglobinopathies. Oct. 2013, Abu Dhabi
121. Karimi M, Haghpanah S, et al. Comparison of the frequency of cholelithiasis in patients with beta-thalassemia intermedia with and without taking Hydroxyurea. 13th International conference on thalassemia and Hemoglobinopathies. Oct. 2013, Abu Dhabi
122. Haghpanah S, Karimi M, et al. Sociocultural challenges of beta-thalassemia major birth in carriers of beta-thalassemia in Iran. 13th International conference on thalassemia and Hemoglobinopathies. Oct. 2013, Abu Dhabi

123. Karimi M. Hydroxyurea as a first line treatment of extramedullary hematopoiesis in patients with beta thalassemia. 13th International conference on thalassemia and Hemoglobinopathies. Oct. 2013, Abu Dhabi
124. Karimi M. Thromboembolism in NTDTs. 13th International conference on thalassemia and Hemoglobinopathies. Oct. 2013, Abu Dhabi
125. Karimi M. Quality impact on safety and efficacy. Clinical experience with original product (EXJADE ®) compared to copy product (Osveral ®) in Iran: efficacy and safety Nicaragua. Ocotber 4 th, 2013
126. Karimi M. Understanding the importance of optimal dosing in effective management of iron overload. EGM Thalassemia Network Kick-off Meeting. October 2013, Abu Dhabi
127. Karimi M. Iron overload and role of chelation therapy in HSCT. 2013 EGM Iron Summit. New Delhi. Sep. 2013 India
128. Karimi M, Zareifar S, et al. Epanddymoma as a secondary malignancy after treatment of non Hodgkin lymphoma. 25th International congress of pediatrics. Oct, 2013 Tehran, Iran
129. Karimi M, Zolghadri J, Nezam M., et al. Inherited Thrombophilia and Recurrent Pregnancy Loss. ISTH. Amsterdam June 29-July 4. 2013.
130. Karimi M, Haghpanah S, Zahedi Z. An experience of use of Traumastem P in control of spontaneous mucosal bleeding in patients with inherited bleeding disorders in Southern Iran. ISTH. Amsterdam June 29-July 4. 2013.
131. Karimi M, Moghaddam M, Gerdabi J., et al. Diffuse intracranial haemorrhage in factor V deficiency: Two case reports. ISTH. Amsterdam June 29-July 4. 2013.
132. Faranoush M, Abolghassemi H, Karimi M., et al. The comparison of efficacy between recombinant activated factor VII (ARYOSEVEN®) and NOVOSEVEN® in patients with congenital factor VII deficiency. ISTH. Amsterdam June 29-July 4. 2013
133. Naderi M, Eshghi P, Karimi M., et al. Intracranial hemorrhage in factor XIII deficiency. ISTH. Amsterdam June 29-July 4. 2013.
134. Faranoush M, Abolghassemi H, Karimi M., et al. Comparision of recombinant coagulation factor VII (ARYOSEVEN®) with NOVOSEVEN® in patients with FVIII & IX deficiency with an inhibitor. ISTH. Amsterdam June 29-July 4. 2013.
135. Karimi M. The status of thalassemia in Iran. 6th INTERNATIONAL THALASSEMIA CONGRESS & SUMMER SCHOOL. Antalya .18-23 APRIL .2013
136. Khaled M. Musallam, Maria D. Cappellini, Shahina Daar, Mehran Karimi., et al. Morbidity Risk In Untreated Patients With B-Thalassemia Intermedia: A Closer Look At The Role Of Iron Overload. 18th Congress of EHA. Stockholm June 2013

137. Karimi M. The effect of iron chelators on cardiac. 6th International Thalassemia Congress & Summer School. Antalya .18-23 April .2013
138. Karimi M, Haghpanah S, Ardestiri R. Attitudes and practices with regard to circumcision in hemophilia patients in southern Iran. The 6th Annual Congress of the European Association for Haemophilia and Allied Disorders. Warsaw. 2013
139. Karimi M, Haghpanah S, Ardestiri R., et al. Attitudes and practices of patients with inherited bleeding disorders and the parents of affected children about family planning and prenatal diagnosis in southern Iran. The 6th Annual Congress of the European Association for Haemophilia and Allied Disorders. Warsaw. 2013.
140. Karimi M. An overview of diagnosis and management of FXIII deficiency in Iran. Opportunities and challenges in the clinical management of rare bleeding disorders in Iran &Lebanon. Lebanon. March, 2013.
141. Karimi M. Use of Exjade in iron chelation therapy: multi-center experience. Exjade quality workshop and site visit. Switzerland. March, 2013
142. IranSenemar S, Karimi M, et al. Effect of MTHFR and plasma homocysteine levels in premature coronary Atherosclerotic disease in south Iran. 7th Middle east cardiovascular congress. Apr. 2013 Istanbul, Turkey.
143. Karimⁱ M, Haghpana^h S, Bagheri MH, et al. Frequency and distribution of asymptomatic brain lesions in patients with β-thalassemia intermedia. 5^{4th} ASH Annual Meeting Abstracts. Atlanta Dec.2012
144. Naderi M, Eshghi P, Karimi M, et al. Prophylactic Program in fxiii Deficient Patients from Iran. 54th ASH Annual Meeting Abstracts. Atlanta Dec.2012
145. Musallam Kh, Cappellini M, Karimi M, et al. Serum Ferritin Levels and Morbidity in β-Thalassemia Intermedia: A 10-Year Cohort Study. 54th ASH Annual Meeting Abstracts. Atlanta Dec.2012
146. Karimi M, Cohan N. HbF induction. 3rd Pan-European Conference on Haemoglobinopathies and Rare Anaemias. Cyprus. Oct. 2012.
147. Karimi M, Haghpanah S, et al. Family planning practice among families with children affected by beta-thalassemia major in southern Iran. 3rd Pan-European Conference on Haemoglobinopathies and Rare Anaemias. Cyprus. Oct. 2012.
148. Karimi M. Acquired Hemophilia: an under-recognized reality. 6th Regional Meeting of the Lebanese Society of Hematology and Blood Transfusion Novo Nordisk Satellite Symposium. Beirut Oct. 2012.
149. Karimi M. Diagnosis, clinical manifestation, treatment and prophylaxis. Thalassemia investigators and thought leaders group meeting. Dubai Nov. 2012.

150. Karimi M. Faxtor X deficiency. Thalassemia investigators and thought leaders group meeting. Dubai Nov. 2012
151. Karimi M. Diagnosis, clinical manifestation, treatment and prophylaxis. Thalassemia investigators and thought leaders group meeting. Dubai Nov. 2012
152. Treatment strategies to prevent/manage thromboembolism in thalassemia and NTDT. EGM Iron Summit. Hong Kong September 2012.
153. Naderi M, Eshghi P, Cohan N, Karimi M. Successful delivery in patients with FXIII deficiency receiving prophylaxis: report of 17 cases in Iran. XXX International congress of the world federation of Hemophilia. Paris July 2012.
154. Karimi M, Haghpanah S, Ardestiri R, et al. Socio-cultural challenges of circumcision in patients with hemophilia in Iran. XXX International congress of the world federation of Hemophilia. Paris July 2012.
155. Beheshtipoor N, Bagheri Sh, Karimi M, et al. The effect of yoga technique on quality of life in Children with hemophilia. XXX International congress of the world federation of Hemophilia. Paris July 2012.
156. Karimi M, SafarpourM, et al. Genotype and phenotype report on patients with combined deficiency of factor V and factor VIII in Iran. XXX International congress of the world federation of Hemophilia. Paris July 2012.
157. Karimi M, Nasirabadi Sh, Mahmoodi M, et al. Phenotypic bleeding penetrance in female carriers of rare inherited coagulation deficiency. XXX International congress of the world federation of Hemophilia. Paris July 2012.
158. Karimi M, Haghpanah S, Bordbar M, et al. Experience on using prothrombin complex concentrate (PCC) in urgent warfarin reversal: an Iranian survey. XXX International congress of the world federation of Hemophilia. Paris July 2012.
159. Karimi M, Haghpanah S, Abdolhamid Shariat, et al. Cerebral Artery Velocity in Patients with β -Thalassemia Intermedia Compared to β -Thalassemia Major Using Transcranial Doppler Ultrasonography. ASH Dec. 2012
160. Savoia A, Kunishima Sh, Karimi M, et al. International Consortium for the Study of Clinical and Molecular Aspects of Bernard-Soulier Syndrome. ASH Dec. 2012
161. Napolitano M, Dolce A, Karimi M, et al. Management of the Sponataneous Bleeding Episodes in Factor VII Deficiency. A Prospective Evaluation of the STER. ASH Dec. 2012
162. Naderi M, Eshghi P, Karimi M, et al. Successful delivery in patients with FXIII deficiency receiving prophylaxis: Report of 17 cases in Iran. ASH Dec. 2012

163. Karimi M, Vafafar A, Haghpanah S, et al. Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran. The International Society on Thrombosis and Haemostasis.2011, Japan.
164. Menegatti M, Palla R, Karimi M, et al. A recurrent P.GLY43ASP substitution of coagulation Factor X (FX) impaires intracellular trafficking and functional activity causing a severe FX deficiency in four patients. International Society on Thrombosis and Haemostasis.2011, Japan.
165. Geffen M, Peyvandi F, Menegatti M, Karimi M, et al. Relation of bleeding tendency in rare bleeding disorders with deficiencies in Factor II, V, VII, X, XIII, and Fibrinogen and simultaneous thrombin and plasmin generation. International Society on Thrombosis and Haemostasis.2011, Japan.
166. Karimi M, Saki N, Saki F, et al. D-dimer level in pediatric patients with solid and hematologic malignancies, Shiraz, Southern Iran. International Society on Thrombosis and Haemostasis.2011, Japan.
167. Karimi M, Haghpanah S. Cerebral thromboembolic events in patients with beta-thalassemia: a systematic-review. International Society on Thrombosis and Haemostasis.2011, Japan.
168. Karimi M. Long term effects of hypoparathyroidism in thalassemia. The First Qatar Thalassemia Forum On Growth and Endocrine Complications of Thalassemia & The First Meeting of The International Group For Studying Endocrine Complications of Thalassemia (I-CET). Oct.2011, Qatar.
169. Karimi M. Growth and development. Thalassemia Iron Summit. Apr.2011, Dubai.
170. Karimi M. Experience with chelation therapy in Iran. Thalassemia Iron Summit. Apr.2011, Dubai.
171. Karimi M. Use of Exjade in iron chelation therapy: multi-center Iran experience. Exjade Copy Advisory Board. Sep.2011, Dubai.
172. Karimi M. Use of Iron chelation in malignancy Clinical Case 6: Presentation and Discussion. Exjade Copy Advisory Board. Sep.2011, Dubai.
173. Karimi M, Dehghani J, Afrasiabi AR., et al. Correlation Between Mean Corpuscular Volume and Mean Corpuscular Hemoglobin With Beta Thalassemia Mutations in Southern Iran. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
174. Yavarian M, Mahdavi MR, Karimi M, Roshan P, et al. Detection of Hb Setif in north Iran and the question of its origin: Iranian or multiethnic? 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.

175. Dehbozorgian J, Imanifard J, Dehghani J, Karimi M, et al. Diagnostic Problem in Combined HB H Disease and Heterozygote Beta thalassemia. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
176. Musallam K, Karimi M, et al. A Closer Look at Pulmonary Hypertension Risk in Patients with Thalassemia Intermedia. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
177. Dehghani J, Karimi M, Afrasiabi AR., et al. Correlation between HBA2 with Beta Thalassemia Mutations in Southern Iran. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
178. Afrasiabi AR., Karimi M, Dehghani J, et al. Beta Thalassemia Screening through Prenatal Diagnosis in Southern Iran, A Cohort Study. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
179. Javanmardi E, Dehghani J, Karimi M, et al. Correlation of C36-37 Mutation of β Globin Gene With Informative Sites In Haplotype Analysis, In Southern Iran. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
180. Zahedi Z, Karimi M, Beheshtipoor N. Comparative survey in anxiety level in employed and unemployed patients with major beta thalassemia in Iran. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
181. Zahedi Z, Karimi M. Quality of life in married patients with beta thalassemia in Iran. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
182. Karimi M, Haghpanah S, Yavarian M, et al. Long term use of hydroxyurea in patients with β -thalassemia in southern Iran. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
183. Karimi M, Haghpanah S. Cerebral thrombosis in patients with beta-thalassemia: a mini-review. 12th International conference on thalassemia & haemoglobinopathies and 14th International TIF Conference for patients & parents. 11-147 May 2011, Turkey.
184. Mehramiri A, Parand S, Haghpanah S, Karimi M. Attitudes of haemophilic patients towards their health and socio-economic problems in Iran. Haemophilia. 2012 Jan; 18(1):122-8.

185. Karimi M. How to prepare and support affected women to deal with the medical condition in Iran. The 4th International Symposium on Womens's Health Issue in Thrombosis and Haemostasis 2011, Vol 127, suppl 3.
186. Amooee S, Samsami A, Jahanbakhsh J, Karimi M. The pregnancy outcome in patients with minor b-thalassemia. The 4th International Symposium on Womens's Health Issue in Thrombosis and Haemostasis 2011, Vol 127, suppl 3.
187. Karimi M. Unusual extramedullar hematopoiesis presentation as a left temporal mass in a patient with blood transfusion dependent beta-thalassemia. 3rd Hematology Oncology Summit 2011.
188. Karimi M, Yavarian M, Afrasiabi A, Ramzi M, et al. The impact of Prothrombin 20210A polymorphism and factor V Leiden on deep vein thrombosis in the south Iranian patients. 21st International congress on thrombosis 2010, Italy, vol 37, suppl 1.
189. Taher A, Musallam K, Karimi M, et al. Risk factors for venous thromboembolic Events in splenectomized patients with thalassemia Intermedia .21st International congress on thrombosis 2010, Italy, vol 37, suppl 1.
190. Afrasiabi A, Karimi M, Artoni A, et al. Normal delivery of a known Bernard soulier syndrome case, with massive bleeding which controlled by RFVII. 21st International congress on thrombosis 2010, Italy vol 37, suppl 1.
191. Karimi M, Rezaeifarid, M. Bone mineral density in Iranian hemophilic patients: the first experience in the south of Iran. XXIXth International congress of the world federation of Hemophilia 2010, Argentina, vol 16, suppl 4.
192. Haghpanah S, Vafafar M, Karimi M, et al. Use of Glubran 2 and Glubran tissue skin adhesive in patients with hereditary bleeding disorders undergoing circumcision and dental extraction. XXIXth International congress of the world federation of Hemophilia 2010, Argentina , vol 16, suppl 4.
193. Rezazadeh S, Haghigat A, Karimi M, et al. Evaluation of intra articular rifampicin in reducing pain, hemarthrosis and improving joint motions in hemophilic arthropathy. XXIXth International congress of the world federation of Hemophilia 2010, Argentina, vol 16, suppl 4.
194. Beheshtipoor N, Karimi M, et al. Evaluation of Sports and exercises in patients with hemophilia. XXIXth International congress of the world federation of Hemophilia 2010, Argentina, vol 16, suppl 4.
195. Karimi M, Afrasiabi A, Beheshtipoor N, et al. Frequency, clinical manifestations and management of rare bleeding disorders in Fars province, Southern Iran. XXIXth International congress of the world federation of Hemophilia 2010, Argentina, vol 16, suppl 4.
196. Karimi M. Supporting women affected by congenital bleeding disorders in Iran. XXIXth International congress of the world federation of Hemophilia July 2010.Argentina.

197. Karimi M, Bordbar MR, Zareifar S, Hamidi R, Mehravar Z. Unusual presentation of T-cell non-hodgkin lymphoma with multiple skin nodules. 6th Congress of the SIOP Asia. Iran-Kish Island. IJBC, Vol 2, Suppl 1, March 2010
198. Bordbar MR, Shahriari M, Karimi M. Leukemic infiltration of the appendix as an unusual site of extramedullary relapse report of two cases and review of the literature. 6th Congress of the SIOP Asia. Iran-Kish Island. IJBC, Vol 2, Suppl 1, March 2010
199. Karimi M, Dialameh Z, Haghigat M. Study of protective effect of breast feeding against lymphoma and leukemia in childhood. 6th Congress of the SIOP Asia. Iran-Kish Island. IJBC, Vol 2, Suppl 1, March 2010
200. Karimi M, Azarkeivan A, Hoofar H, Eslami M. Malignancies in patients with B-thalassemia major and B-thalassemia intermedia: A multicenter study in Iran. 6th Congress of the SIOP Asia. Iran-Kish Island. IJBC, Vol 2, Suppl 1, March 2010
201. Zekavat OR, Samani SM, Nasibi S, Karimi M. Clinical evaluation of the new topical An-esthetic formulation in β-thalassemia major patients. The Journal of Applied Research. Vol. 9. No. 3, 2009
202. Yavarian M, Karimi S, Ahmadian L, Karimi M, et al. Frequency of factor V leiden and prothrombin 20210A as thrombotic and genetic risk factors for preeclampsia in the South Iranina province. XXII Congress. The International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, USA, Vol 7, Suppl 2
203. Karimi M, Pourmohamadi K, Bastani P. Quality of life in hemophilia complicated by inhibitors. XXII Congress. XXII Congress. The International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, USA, Vol 7, Suppl 2
204. Karimi M, Cohan N, Yavarian M, Ardeshtiri Y, et al. Frequency of intracranial hemorrhage among Iranian patients with rare bleeding disorders. XXII Congress. The International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, USA ,Vol 7, Suppl 2
205. Karimi M, Yavarian M, Ramzi M, Zakernia M, et al. Frequency of hereditary thrombophilic risk factors in Iranian patients with deep vein thrombosis. XXII Congress. The International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, USA ,Vol 7, Suppl 2
206. Karimi M, Ahmadkia daliri A, Pourmohammadi K, Bastani P. The impact of inhibitors on the cost of clotting factor replacement therapy in hemophilia A in South of Iran. XXII Congress. The International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, USA ,Vol 7, Suppl 2
207. Karimi M, Cohan N, Ardeshtiri Y, Beheshtipoor N, et al. Frequency of menorrhagia among Iranian women with rare bleeding disorders. XXII Congress. The International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, USA ,Vol 7, Suppl 2

208. Karimi M, Amoei S, Zolghadri J, Afrasiabi A. Survey of coagulation disorders in women with idiopathic menorrhagia. 3rd International Symposium on Women's Health Issues in Thrombosis and Haemostasis. February 6-8, 2009, Prague, Czech Republic.
209. Karimi M, Zolghadri J, Nesam M, Afrasiabi A. Inherited thrombophilia and recurrent pregnancy loss. 3rd International Symposium on Women's Health Issues in Thrombosis and Haemostasis. February 6-8, 2009, Prague, Czech Republic.
210. Karimi M, Emad Marvasti V, Afrasiabi A, Safaei Jahromi F. The hematological, adverse effects and clinical responses of beta-thalassemia intermedia patients to hydroxyurea: 10 years experience in Iran. International Thalassemia Conference. 11th international conference on thalassemia & haemoglobinopathies and 13th International TIF Conference for thalassemia patients & parents. 8-11 October 2008, Singapore.
211. Karimi M, Emad Marvasti V, Karamifar H, Khabiri M, Jabbarian A, Safaei Jahromi F. Gynecomastia in thalassemia major adolescent boys. International Thalassemia Conference. 11th international conference on thalassemia & haemoglobinopathies and 13th International TIF Conference for thalassemia patients & parents. 8-11 October 2008, Singapore.
212. Karimi M, Emad Marvasti V, Mehrabnejad S, Mohagheghi P, Afrasiabi A, Dehbozorgian J. Prevalence of delta beta thalassemia in Southern Iran. International Thalassemia Conference. 11th international conference on thalassemia & haemoglobinopathies and 13th International TIF Conference for thalassemia patients & parents. 8-11 October 2008, Singapore.
213. Karimi M, Emad Marvasti V, Riahi Alam M, Hoseini J, Shoja L. Major cause of hospital admissions in major thalassemia patients during 2005-2008. International Thalassemia Conference. 11th international conference on thalassemia & haemoglobinopathies and 13th International TIF Conference for thalassemia patients & parents. 8-11 October 2008, Singapore.
214. Karimi M, Emad Marvasti V, Moshiri A, Rasekhi A, Kumar PV, Safaei Jahromi F. Magnetic resonance imaging (MRI) evaluation of liver iron concentration in patients with beta-thalassemia major. International Thalassemia Conference. 11th international conference on thalassemia & haemoglobinopathies and 13th International TIF Conference for thalassemia patients & parents. 8-11 October 2008, Singapore.
215. Karimi M, Emad Marvasti V, Moshiri A, Rasekhi A, Kumar PV, Safaei Jahromi F. Magnetic resonance imaging (MRI) evaluation of liver iron concentration in patients with beta-thalassemia major. International Thalassemia Conference. 11th international conference on thalassemia & haemoglobinopathies and 13th International TIF Conference for thalassemia patients & parents. 8-11 October 2008, Singapore.
216. Karimi M, Fotouhi Ghiam A, Hashemi A, Afrasiabi A. Thalassemia minor is not a risk factor for suicide, impulsivity and aggression: a reverse approach. International Thalassemia Conference.

- 11th international conference on thalassemia & haemoglobinopathies and 13th International TIF Conference for thalassemia patients & parents. 8-11 October 2008, Singapore.
217. Afrasiabi A, Karimi M, Shahriari M, et al. Beta globin's single nucleotide polymorphisms frequency in beta thalassemia carrier in south of Iran. International Thalassemia Conference. 11th international conference on thalassemia & haemoglobinopathies and 13th International TIF Conference for thalassemia patients & parents. 8-11 October 2008, Singapore.
218. Karimi M, Shafieian R. Prophylactic effect of recombinant factor VIIa in two patients with congenital factor VII deficiency. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
219. Karimi M, Afrasiabi A, Peyvandi F, Margalione M, Garagiola I, Nasirabadi S. Carrier detection and prenatal diagnosis in high risk families. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
220. Karimi M, Amirkhani A, Afrasiabi A, Beheshtipoor N, Ardestiri R. Evaluation of annual coagulation disorders in south Iran: 6 years experience. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
221. Karimi M, Afrasiabi A, Beheshtipoor N, Ardestiri R, Dehbozorgian J, Yavarian M. An overview to hemophilia inhibitor patients in southern Iran. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
222. Menegatti M, Karimi M, Afrasiabi A, Peyvandi F. Report on ten new patients with congenital factor X deficiency and the associated mutations. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
223. Menegatti M, Spreafico M, Karimi M, Shetty S, Srivastava A, Peyvandi F. Prevalence of gain-of-function factor V leiden and prothrombin G20210A in a large cohort of patients with rare bleeding disorders. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
224. Beheshtipoor N, Karimi M. The effect of self infusion and self care on referring to hospital in hemophilic patients. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
225. Beheshtipoor N, Haghnegahdar A, Karimi M, Ardestiri R. Violence by husbands among mothers of children with hemophilia. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
226. Beheshtipoor N, Haghnegahdar A, Karimi M. Guidelines for communication with hemophilia adolescent patients. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
227. Karimi M, Afrasiabi A, Amoei S, Nasirabadi S, Zolghadri J. Survey of coagulation disorders in women with idiopathic menorrhagia. Istanbul, Turkey June 1-5, Volume 14, Supplement 2, 2008
228. Karimi M. Alternative medical treatment of AUB in women with coagulation disorders. The 1st Iranian Seminar of Thrombosis & Homeostasis with considering obstetric & gynecologic complications. Mashhad, Iran, May 14-15, 2008.

229. Karimi M. Hereditary Thrombophilia. The 1st Iranian Seminar of Thrombosis & Homeostasis with considering obstetric & gynecologic complications. Mashhad, Iran, May 14-15, 2008
230. Karimi M. Prophylactic effect of rFVIIa in two newborns with severe factor VII deficiencies using port-a-cath. 9th Novo Nordisk symposium on Haemostasis management. 14-16 Nov. 2007, Barcelona, Spain.
231. Derakhshan A, Karimi M, Ghadimi Moghadam A, Basiratnia M. Comparative evaluation of renal findings in thalassemia major and thalassemia intermedia in children and young adults. 14th congress of the International Pediatric Nephrology Association IPNA. 31 August – 4 September, 2007 Budapest, Hungary
232. Karimi M, Afrasiabi R, Zolghadri Z, Samsami Z, Dehbozorgian J, Yavarian M. Influence of inherited thrombophilia with recurrent pregnancy loss. XXIst Congress of the International Society on Thrombosis and Haemostasis. 53rd Annual SSC Meeting. 6-12 July 2007, Geneva- Switzerland
233. Spreafico M, Menegatti M, Garagiola I, Palla R, Tagliabue L, Karimi M, Lak M. et al. Database on rare bleeding disorder (RBDS): phenotype and genotype analysis on 400 affected patients. XXIst Congress of the International Society on Thrombosis and Haemostasis. 53rd Annual SSC Meeting. 6-12 July 2007, Geneva- Switzerland
234. Karimi M, Pishva N, Shahbazi M, Afrasiabi A, Jamalian N. Determination of protein C level in neonates with sepsis like illness. XXIst Congress of the International Society on Thrombosis and Haemostasis. 53rd Annual SSC Meeting. 6-12 July 2007, Geneva- Switzerland
235. Karimi M, Jafari H, Akbari A, Afrasiabi A, Dehbozorgian J, Ardeshtiri R. Factor XI deficiency in Southern Iran and review of literature. XXIst Congress of the International Society on Thrombosis and Haemostasis. 53rd Annual SSC Meeting. 6-12 July 2007, Geneva- Switzerland
236. Artoni A, Afrasiabi A, Lecchi A, Karimi M, Ashouri E, et al. Genetic characterization of patients with Bernard-Soulier Syndrome and their relatives from Southern Iran. XXIst Congress of the International Society on Thrombosis and Haemostasis. 53rd Annual SSC Meeting. 6-12 July 2007, Geneva- Switzerland
237. Menegatti M, Palla R, Afrasiabi A, Karimi M, De Cristofaro R, et al. Kinetics studies of a naturally occurring mutation on factor X (FX) Gene (G222D). XXIst Congress of the International Society on Thrombosis and Haemostasis. 53rd Annual SSC Meeting. 6-12 July 2007, Geneva- Switzerland
238. Afrasiabi AR, Karimi M, Rahiminezhad MS, Dehbozorgian J, Yavarian M, Akbari A, et al. Prenatal diagnosis of Beta-Thalassemia in the South of Iran. 4th Congress of Iranian Pediatric Hematology and Oncology Society. 7-9 September 2006, Kerman, Iran.

239. Dehbozorgian J, Karimi M, Afrasiabi AR, Yavarian M, Badiebard L, Akbari A, et al. The importance of differential diagnosis of alpha-thalassemia in prenatal diagnosis. 4th Congress of Iranian Pediatric Hematology and Oncology Society. 7-9 September 2006, Kerman, Iran.
240. Karimi M, Moosavizadeh K, Falahi MJ. Adverse effects of hydroxyurea in Beta-thalassemia intermedia patients: 8 years experience and review of literature. 4th Congress of Iranian Pediatric Hematology and Oncology Society. 7-9 September 2006, Kerman, Iran.
241. Imanieh MH, Akbari A, Karimi M. Prevalence of HCV antibody positivity in multitransfused thalassemic patients Dastgheib Hospital, Shiraz-Iran. 4th Congress of Iranian Pediatric Hematology and Oncology Society. 7-9 September 2006, Kerman, Iran.
242. Bazrgar M, Karimi M, Fathzadeh M, Senemar S, Peiravian F, Shojaei A, Saadat M. Frequency of apolipoprotein E alleles in healthy population of Iranian thalassemia patients. 14th National & 2nd International Conference of Biology Tarbiat Modares University, Tehran, Iran 2006
243. Karimi M, Lak M, Afrasiabi A, Zangneh H, Mannucci P, Peyvandi F. Arg77His: a common mutation of factor XIII deficiency in Iran. Haemophilia Word Congress. 21-25 May 2006, Vancouver, Canada.
244. Beheshtipoor N, Karimi M. Home treatment in Iranian patients with hemophilia. 21-25 May 2006, Vancouver, Canada.
245. Eshghi P, Jazebi M, Hoofar H, Karimi M, et al. Multicentric screening of factor VIII inhibitor in 355 hemophilia A patients in Iran 2005. 21-25 May 2006, Vancouver, Canada.
246. Afrasiabi A, Lecchi A, Karimi M, Ashouri E, et al. Clinical, biological and genetic characterization of a cohort of patients with Bernard-Soulier syndrome in South Iran. 21-25 May 2006, Vancouver, Canada.
247. Monaldini L, Duga S, Asselta R, Peyvandi F, Karimi M, et al. Two novel homozygous mutations in the fibrinogen genes identified in two Iranian afibrinogenemic patients. 21-25 May 2006, Vancouver, Canada.
248. Rahamanian S, Karimi M, Zangeneh H, Pasalar M. Health vs. cost assessment in Iranian hemophiliac patients. 21-25 May 2006, Vancouver, Canada.
249. Karimi M, Afrasiabi A, Zangeneh H, Dehbozorgi J, et al. Von willebrand disease, a modifier of bleeding in FXI deficiency. 21-25 May 2006, Vancouver, Canada.
250. Karimi M, Marvasti VE, Motazedian S, Sharifian M. Is β thalassemia trait a protective factor against hypertension in young adults? 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
251. Karimi M, Nikrooz P, Kashef S, Davatolagh Z. Survey on RBC alloimmunization in blood transfusion dependent beta-thalassemia major patients in Iran, 2004. 10th International Conference

- on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
252. Karimi M, Kazeroni T, Jabarian A, Eghlidi MS, Karamizadeh Z. Evaluation of the prevalence of ovarian cysts in girls above fourteen years old with major thalassemia in Southern Iran, 2004. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
253. Karimi M, Karamifar H, Sobhani N. Insulin-like growth factor-1 in β thalassemia minor children. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
254. Karimi M, Afrasiabi A, Dehbozorgian J, Shahcheraghi F, et al. Long term follow up of ferritin level in H.C.V. sero positive transfusion dependent thalassemia patients.
255. Karimi M, Khanlari M. Cerebrovascular accident in β-thalassemia major (B-TM) and intermedia (B-TI). 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
256. Bazrgar M, Peiravian F, Fathzadeh M, Karimi M. Left ventricular dysfunction in β-thalassemia major: A correlation study between hematological parameters and iron chelation with echocardiographic findings. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
257. Karimi M, Marvasti VE, Motazedian S, Sharifian M. Is β-thalassemia trait a protective factor against hypertension in young adults? 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
258. Johari Sh, Karimi M. Socioeconomical and cultural factors affecting family planning among families of thalassemic children in Southern Iran. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
259. Marvasti VE, Karimi M. Is β-thalassemia trait a risk factor for developing depression in young adults? 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
260. Karimi M, Afrasiabi A, Askarinejad A, Ashrafi A. A study on the prevention and decline of thalassemia through increase awareness and family planning. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.

261. Afrasiabi A, Karimi M, Zeinali S, Dehbozorgian J, et al. Prevalence of beta-gene mutations in South of Iran. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
262. Afrasiabi A, Karimi M, Dehbozorgian J, et al. Molecular prenatal diagnosis in South of Iran. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
263. Afrasiabi A, Karimi M, Zeinali S, et al. Prevalence of beta-gene mutations in South of Iran. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
264. Dehbozorgian J, Karimi M, Badieefar L, et al. Experience of α/β chain biosynthesis and application in premarital screening. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
265. Karimi M, Ashrafi A, Askarnejad A, et al. Screening program of beta-thalassemia and the reasons of new cases in Southern Iran. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
266. Karimi M, Fotuhi A, Hashemi, et al. Bone mineral density in beta-thalassemia major and intermedia. 10th International Conference on Thalassemia & Haemoglobinopathies & 12th International TIF Conference for Thalassemia Patients and Parents. 7-10 January 2006, Dubai, UAE.
267. Imanieh MH, Karimi M, Jahaniar Moqadam F, Mowla A. Comparison of amantadine plus interferon-a versus interferon-a alone in the treatment of hepatitis C infection in β-thalassemia major patients in Shiraz, Iran. International Saudi Symposium of Pediatric Hematology/Oncology. 21-23 November 2005, Jadeh, Saudi Arabia.
268. Karimi M, Shadmanie A, Shadmanie Gh, Safaei Jahromi F. Survival analysis and factors affecting survival in 0-18 year old patients with hematogenous malignancies who referred to South of Iran between 1991-2003. International Saudi Symposium of Pediatric Hematology/Oncology. 21-23 November 2005, Jadeh, Saudi Arabia.
269. Safaei Jahromi F, Ayatollahi M, Ramzi M, Entezam M, Karimi M. Survey of anticardiolipin antibodies in childhood acute lymphoblastic leukemia: Prevalence and clinical significance. International Saudi Symposium of Pediatric Hematology/Oncology. 21-23 November 2005, Jadeh, Saudi Arabia.

270. Ayatollahi M, Ramzi M, Karimi M, Entezam M. Anticardiolipin antibodies in adult and childhood acute leukemia. International Saudi Symposium of Pediatric Hematology/Oncology. 21-23 November 2005, Jadeh, Saudi Arabia.
271. Alireza Fotouhi Ghiam, Mohammad Hadi Imanieh, Zahra Hashemi, Mehran Karimi. Investigation of helicobacter pylori infection in beta-thalassemia major patients with recurrent abdominal pain. Turkish Journal of Hematology, xxxth World Congress of the International Society of Hematology. Sup Vol. 22, 28 Sep. - 2 Oct. 2005, Istanbul, Turkey.
272. Alireza Fotouhi Ghiam, Alireza Hashemi, Mehran Karimi, Saeid Alinejad, et al. Bone mineral density in beta-thalassemia major and intermedia. Turkish Journal of Hematology, xxxth World Congress of the International Society of Hematology. 28 Sep.- 2 Oct. 2005, Istanbul, Turkey.
273. Alireza Hashemi, Alireza Fotouhi Ghiam, Soudabeh Sadeghi Jahromi, Shahin Toobaee, Mehran Karimi. Substance abuse in Iranian patients with haemophilia. Turkish Journal of Hematology, xxxth World Congress of the International Society of Hematology. 28 Sep.- 2 Oct. 2005, Istanbul, Turkey.
274. Mehran Karimi. The hematological and clinical responses of thalassemia intermedia patients to hydroxyurea during a 7 years therapy in Iran. The 4th middle East Thalassemia Investigators and Thought Leaders Meeting. 30 Sep. 2005, Esma Sultan, Istanbul, Turkey.
275. Mehran Karimi. Developing hemophilia care programs. The World Federation of Hemophilia's. 9th Musculoskeletal Congress. 9-11 Sep. 2005, Istanbul, Turkey.
276. Karimi M. Evaluation of child thrombotic disorders and approach to it. 5th National Iranian Congress of Hematology, Oncology & Nursing. 22-24 June 2005, Shiraz, Iran.
277. Karimi M., Ayatollahi M, Ramzi M, Aghdaie M. Survey of anticardiolipin antibodies in childhood acute lymphoblastic leukemia: Prevalence and Clinical Significance. 5th National Iranian Congress of Hematology, Oncology & Nursing. 22-24 June 2005, Shiraz, Iran.
278. Karimi M., Amipour A., Hashemi A., Fotouhi Ghiam A, Doroudchi M., Ghaderi A.. Survey of anti-viral antibodies in acute childhood leukemia. 5th National Iranian Congress of Hematology, Oncology & Nursing. 22-24 June 2005, Shiraz, Iran.
279. Karimi M. Successful control of central nervous system (CNS) bleeding in 2 newborns with severe factor VII deficiency using rFVIIa administered via port-a-Cath. 8th Novo Nordisk Symposium on Haemostasis Management. 11-13 May 2005, Copenhagen, Denmark.
280. Ayatollahi M, Ramzi M, Karimi M, Entezam M, et al. Anticardiolipin antibodies in patients with some hematological malignancies. The 3rd Regional Conference of Asian Pacific Organization for Cancer prevention (APOCP). GI Cancer Control. 25-27 April 2005, Zibakenar, Rasht, Iran.

281. Karimi M., Dehghani M., Ardesiri R. and Jahromi FS. Mortality rate among hemophilia in Southern of Iran: 20 years follow-up. World Federation Hemophilia Congress. 17-21 Oct 2004, Bangkok, Thailand.
282. Karimi M., Karegar M., Ardesiri R. and Beheshtipoor N. Prevalence of inhibitors among hemophilia patients in Southern part of Iran. World Federation Hemophilia Congress. 17-21 Oct 2004, Bangkok, Thailand.
283. Peyvandi F., Menegatti M., Kavakli K., Karimi M. and Mannucci PM. Molecular evaluation of a naturally occurring mutation on factor X gene (Gly 222 Asp) causing severe FX deficiency. World Federation Hemophilia Congress. 17-21 Oct 2004, Bangkok, Thailand.
284. Beheshtipoor N., Karimi M. The effect of self treatment education on referring hemophilia patients to hospital. World Federation Hemophilia Congress. 17-21 Oct 2004, Bangkok, Thailand.
285. Mowla A., Karimi M., Afrasiabi A.R. Glucose tolerance test in major thalassemic patients with and without hepatitis C virus infection; An experience in Southern Iran. 4th National Iranian Congress of Hematology & Oncology and Nursing Meetikng, 23-25 June 2004, Mashhad, Iran.
286. Karimi M., Yarmammady H. Analysis of intelligence quotient in patients with homozygous beta-thalassemia in Shiraz, Iran. 9th congress of the European Hematology Association. 10-13 June 2004, Geneva, Switzerland.
287. Rahimi Z., Merat A., Haghshenass M., Karimi M., et al. XMN I site polymorphism 5' to gama G in sickle cell disease in Southern Iran. 9th congress of the European Hematology Association. 10-13 June 2004, Geneva, Switzerland.
288. Mohammad Amin Kashef, Sara Kashef, Farhad Hanjani, Mehran Karimi, et al. Hodgkin's lymphoma developing in a 4.5 year-old girl with hyper-IgE syndrome. The Australian Health & Medical Research Congress 2004, Australia.
289. Karimi M., Habibzadeh F., De Sanctis V. Hypoparathyroidism with Extensive intracerebral calcification in patients with β -thalassemia major. 2nd Conference of Iranian Pediatric Hematology and Oncology Society. 28-30 April 2004, Kish, Iran.
290. Beheshtipoor N., Karimi M. Carrier detection and fetal diagnosis in hemophilia. 2nd congress of preventive non-contiguous diseases. 7-9 Mar. 2004, Tehran, Iran,
291. Beheshtipoor N., Haghnegahdar A., Karimi M. Cardiac complications in β -thalassemia major patients in Shiraz-Iran. 2nd congress of preventive non-contiguous diseases. 7-9 Mar. 2004, Tehran, Iran.
292. Beheshtipoor N., Karimi M. Carrier detection and fetal diagnosis in β -thalassemia major. 2nd congress of preventive non-contiguous diseases. 7-9 Mar. 2004, Tehran, Iran.
293. Karimi M., Karamifar H. Short stature in β -thalassemia minor subjects. 45th Annual meeting of the ASH. 6-9 Dec. 2003, Sandiego, USA.

294. Karimi M., Yarmohammadi H., Safaei Jahromi F. Common and uncommon presentations of childhood leukemia and lymphoma: A five-year analysis of 367 patients in a large referral center in Iran. 16th international congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
295. Yarmohammadi H., Safaei Jahromi F., Karimi M. Incidence of cancer in children of Fars province: A 10-year descriptive epidemiological study. 16th international congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
296. Alavi M., Nabavizadeh A., Mowla A., Karimi M. The role of whole body bone scan in acute lymphoblastic leukemia. 16th international congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
297. Rasekhi AR., Mojarrab M., Afrasiabi R., Karimi M. Neuroblastoma: Epidemiological study of signs and symptoms and staging: 1992-2001. 16th international congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
298. Asadi-Pooya AA., Karamizadeh Z., Rahiminejad MS., Shahriari M., Kraimi M. Disturbances in calcium metabolism in childhood lymphoblastic leukemia, before and after chemotherapy. 16th international congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
299. Pishva N., Karimi M. A pilot study on hemoglobinopathy in neonates with indirect hyperbilirubinemia in Nemazee Hospital, Shiraz-Iran. 16th international congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
300. Cheriki S., Alborzi A., Karimi M., Oboodi B. The incidence of bacterial infections in neutropenic patients aged < 15 years admitted to Shiraz University Hospitals: 1379-80. 16th international congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
301. Zakerinia M., Karimi M., Nourani Khojasteh H., Ramzi M., Haghshenas M., Ejaz Ahmad. Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with novoseven (Factor VII Activated) after allogeneic bone marrow transplantation. 16th international congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
302. Peiravian F., Sharifkazemi MB, Shojaae E., Karimi M., Samim MM. Role of ECG holter monitoring in early detection of occult arrhythmia in thalassemia major. 16th international congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
303. Asadi-Pooya AA., Karamizadeh Z., Bagheri M.H., Rasekhi A.R., Karimi M., Shahriari M., Rahiminejad M.S. Radiographic findings in childhood lymphoblastic leukemia. 16th international

- congress of geographic medicine advances in basic and clinical oncology. 1-4 December 2003, Shiraz, Iran.
304. Alborzi A., Karimi M., et al. The incidence of bacterial infections in neutropenic patients (Age <15 years) admitted in Shiraz University Hospitals (2000-2001). 2nd International Young Medics Conference, 26-28 Sept. 2003, Armenestan.
305. Garagiola I., Peyvandi F., Karimi M., Lavoretano S., Mannucci P., Fondazione L. Molecular characterisation of vascular endothelial growth factor (VEGF) gene and evaluation of VEGF plasma levels in patients post myocardial infarction with and without collateral blood vessels. 8th Annual Congress of the European Hematology Association. 12-15 June 2003, Lyon, France.
306. Menegatti M., Garagiola I., Karimi M., Peyvandi F. Bleeding symptoms in patients with combined FVII+FX deficiency. 8th Annual Congress of the European Hematology Association. 12-15 June 2003, Lyon, France.
307. Karimi M., Johari Sh. Investigation of acceptance of PND (Prenatal Diagnosis) and abortion of thalassemia affected fetus among thalassemics over 16 years of age and parents of disease children. The 9th International Conference on Thalassemia and Hemoglobinopathies. Terrasini. 15-19 October 2003, Palermo, Italy.
308. Karimi M., Nica Cappellini M., Castelli R. Extramedullary haematopoiesis in Iranian thalassemia intermedia patients: report of two cases. The 9th International Conference on Thalassemia and Hemoglobinopathies. Terrasini. 15-19 October 2003, Palermo, Italy.
309. Karimi M. Evaluation of efficacy of instruction among beta thalassemia major patients in Shiraz – Iran. The 9th International Conference on Thalassemia and Hemoglobinopathies. Terrasini. 15-19 October 2003, Palermo, Italy.
310. Yavarian M, Karimi M, Hartevelde C, et al: Response to hydroxyurea treatment in b-thalassemia intermedia patients in South-Iran. The 9th International Conference on Thalassemia and Hemoglobinopathies. Terrasini. 15-19 October 2003, Palermo, Italy.
311. Zarbakhsh B., Zeinali S., Karimi M., Mohammadi M.S., et al: α - Thalassemia Genotypes in Iran. The 9th International Conference on Thalassemia and Hemoglobinopathies. Terrasini. 15-19 October 2003, Palermo, Italy.
312. Afrasiabi A, Dehbozorgian J, Asadzadeh R, Karimi M, et al: Compare of M.C.V with Beta gene point mutation. The 9th International Conference on Thalassemia and Hemoglobinopathies. Terrasini. 15-19 October 2003, Palermo, Italy.
313. M. Karimi, PM. Mannucci, A. Mosalaei, et al. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). XIX Congress of the International Society on thrombosis and haemostasis. 12- 18 July 2003, Birmingham, UK.

314. M. Karimi, M. S. Rahiminejad, T. Karamimaghani. Coagulation disorders in beta-thalassemic patients in Southern Iran. XIX Congress of the International Society on thrombosis and haemostasis 12- 18 July 2003, Birmingham, UK.
315. M. Karimi, H. Yarmohammadi, R. Ardestiri, et al. Inherited coagulation disorders in Southern Iran. XIX Congress of the International Society on thrombosis and haemostasis 12- 18 July 2003, Birmingham, UK.
316. J. Shenoi, M. Karimi, C. Ross, et al. The three I Hemophilic study: a comparative study of the morbidity pattern between Asian Indian, Iranian and Italian PWH. XIX Congress of the International Society on thrombosis and haemostasis 12- 18 July 2003, Birmingham, UK.
317. M. S. Enayat, B. D. M. Theophilus, S. Farjadian, M. Karimi, et al. Identification of factor IX mutations in 17 Iranian families with hemophilia B. XIX Congress of the International Society on thrombosis and haemostasis 12- 18 July 2003, Birmingham, UK.
318. M. Karimipour, S. Zeinali, M. Lak, R. Safaie, N. Nafissi, M. Karimi. Rapid screening of factor IX mutations by SSCP and sequencing in 50 Iranian families. XIX Congress of the International Society on thrombosis and haemostasis 12- 18 July 2003, Birmingham, UK.
319. Karimi M. Evaluation of efficacy of instruction among Beta-thalassemia major patients in Shiraz- Iran. 15th international congress of Geographic Medicine and National Congress of Medical Education. 9-11 December 2002, Shiraz, Iran.
320. Karimi M, et al. Epidemiologic and survival rate of childhood rhabdomyosarcoma in Southern Iran. An International symposium of Cancer. 14-16 Oct. 2002, Riadh, Kingdom of Saudi Arabia.
321. Karimi M, Soltani M. Evaluation of local anesthetic EMLA ointment among childhood malignancy. First International Congress of Anesthesiology and Perioperative Medicine. 2-5 Oct. 2002, Shiraz-Iran.
322. Karimi M, Yarmohammadi H: Seasonal variations in the onset of childhood leukemia / lymphoma. 18th UICC international cancer congress, 30 June – 5 July 2002; Oslo, Norway.
323. Karimi M, Martínez di Montemuros F, Danielli MG, et al: Molecular characterization of glucose – 6- phosphate dehydrogenase (G6PD) deficiency in Iran. European hematology association Congress. 6-9 Jun. 2002; Florans, Italy.
324. Karimi M, Peyvandi F, et al: Comparison of acceptability of abortion and PND procedure among hemophilic patients & parents between Iran & Italy. XXV international congress of the world Federation of Hemophilia. 19- 24 May 2002; Seville, Spain.
325. Karimi M, Ardestiri R: Relation of coagulation disorders with ABO & RH blood groups. XXV international congress of the world Federation of Hemophilia & RH. 19- 24 May 2002; Seville, Spain.

326. F. Peyvandi, L. Tagliabue, M. Karimi and P.M. Mannucci. Characterization of nine patients with sever factor XIII deficiency. XXV international congress of the world Federation of Hemophilia & RH. 19- 24 May 2002; Seville, Spain.
327. Karimi M: Prevalence of hypoparathyroidism in β - thalassemia major patients in Shiraz – Iran. First International congress on the complications of thalassemia in Adolescents. 2-4 May 2002, Tehran, Iran.
328. Karimi M, Ghadir N: Evaluation of family planning in 510 β - thalassemia Patient's parents in Shiraz – Iran. First International congress on the complications of thalassemia in Adolescents. 2 – 4 May 2002, Tehran, Iran.
329. Ghavanini AA, Karimi M: Sero prevalence of viral hepatitis among multitransferred thalassemic children in Iran. 18 – 21 October 2001, Athens, Greece.
330. Karimi M, Askarinegad A, Farahmand – beigi M, et al: Regional mapping of the prevalence of β - thalassemia in Fars province. 14th international congress of Geographic Medicine. 5 – 8 Nov. 2001, Shiraz, Iran.
331. Norani Kh, Zakerinia M, Ramzi M, Rahiminejad M, Shahriari M, Karimi M: Bone marrow transplantation in acut myeloid leukemia. First international Iranian congress on cancer. 11- 13 Sep. 2001, Mashhad, Iran.
332. Karimi M, Ghavanini AA: Seroprevalence of HBSAg, anti HCVAb and HIV Ab among heamophilic children in Shiraz – Iran. 6 – 12 July 2001, Paris, France.
333. Karimi M, Ghavanini AA: Diabetes Mellitus in β - thalassemic patients. Conference of Diabetes in the Arab World. 24 – 26 March 2001, Bahrain, Bahrain.
334. Karimi M, Sabri MR: Survey of Cardiac System in 50 β - thalassemic patients in Shiraz. 13th international congress of geographic medicine and the congress of cardiovascular diseases. 2 – 5 October 2000, Shiraz, Iran.
335. Karimi M: Prevalence of HIV seropositive in 490 β - thalassemic patients in Shiraz, Southern of Iran. 13th international congress of geographic medicine and the congress of cardiovascular diseases. 2 – 5 October 2000, Shiraz, Iran.
336. Karimi M. The evaluation of liver functions of thalassemia major patients undergoing bone marrow transplantation. 1st course in thalassemias and sickle cell anemia in the mediterranean. 20 – 22 November 1999, Sestri lavante, Italy.
337. Karimi M: Survey and Rate determination of blood transfusion reactions in thalassemic patients referring to Dastgheib Hospital. 11th international congress of geographic medicine and the congress of ambulatory medicine. 9 – 12 October 1998, Shiraz, Iran.

Publications (current h-index 41):

1. Karimi M, Haghpanah S, Azarkeivan A, et al. Prevalence and Mortality due to Outbreak of Novel Coronavirus Disease (COVID-19) in β -Thalassemias: The Nationwide Iranian Experience. Accepted in British Journal of Hematology (May 2020).
2. Karimi M, De Sanctis V. Implications of SARS-CoV 2 infection in thalassemias: Do patients fall into the “high clinical risk” category? *Acta Biomed* 2020 May 11;91(2):50-56.
3. Lissitchkov T, Madan B, Djambas Khayat , Zozulya N, Ross C, Karimi M, et al. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. *J Thromb Haemost*. 2020 Apr;18(4):815-824.
4. De Sanctis V, Soliman A, Daar Sh,, Karimi M, et al. A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β -Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. *Mediterr J Hematol Infect Dis*. 2020; 12(1): e2020006.
5. Karimi M, Zarei T, Haghpanah S, De Sanctis V, et al. Evaluation of endocrine complications in beta-thalassemia intermedia (β -TI): a cross-sectional multicenter study. *Endocrine*. 2019 Dec 18. doi: 10.1007/s12020-019-02159-6.
6. Karimi M, Haghpanah S, Bahoush G, Ansari S, Azarkeivan A, Shahsavani A, Bazrafshan A, Jangjou A. Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia. *J Pediatr Hematol Oncol*. 2019 Sep; 42(1):23-26.
7. Abtahi F, Abdi A, Jamshidi S, Karimi M, Babaei-Beigi MA, Attar A. Global longitudinal strain as an Indicator of cardiac Iron overload in thalassemia patients. *Cardiovasc Ultrasound*. 2019 Nov 4;17(1):24.
8. De Sanctis V, Soliman AT, El-Hakim, Christou S, Mariannis D, Karimi M, et al. Marital status and paternity in patients with Transfusion- Dependent Thalassemia (TDT) and Non-Transfusion-Dependent Thalassemia (NTDT): an ICET - A survey in different countries. *Acta Biomed*. 2019 Sep 6;90(3):225-237.
9. Mirzaie M, Nasiri M, Karimi M, YavarianM, Kavosi A. FoxO3a Gene Down-regulation in Pathogenesis of Pediatric AcuteLymphoblastic Leukemia. *Indian Journal of Medical and Paediatric Oncology*. 2019 September; 40(3): 381-385.
10. Karimi M, Haghpanah S, Pishdad P, Zahedi Z, Parand S, Safaei S. Frequency of silent brain lesions and aspirin protection evaluation over 3 years follow-up in beta thalassemia patients. *Ann Hematol*. 2019 Oct;98(10):2267-2271.
11. Bordbar M, Bozorgi H, Saki F, Haghpanah S, Karimi M, Bazrafshan A, Zekavat OR. Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran. *J Endocrinol Invest*. 2019 Jun 21. doi: 10.1007/s40618-019-01072-z. [Epub ahead of print]
12. Naderi M, Cohan N, Haghpanah S, Miri-Aliabad G, Shahramian I, Ahmadinejad M, Sadeghi S, Dorgalaleh A, Khazaei HA, Karimi M. Correlation of bleeding score with frequency and severity of bleeding symptoms in FXIII deficiency assessing by the ISTH Bleeding Assessment Tool. *Transfus Apher Sci*. 2019 Aug;58(4):495-497.

13. Eshghi P, Tara SZ, Baghaipour MR, Bordbar MR, Jenabzade A, Habibpanah B, Cohan N, Tavosi H, Bahrami R, Karimi M. Inhibitors against rFVIIa in patients with severe congenital FVII deficiency: A case series. *Haemophilia*. 2019 Aug 19. doi: 10.1111/hae.13839. [Epub ahead of print]
14. Klei TRL, Kheradmand Kia S, Veldthuis M, Dehbozorgian J, Karimi M, et al. A Homozygous Mutation on the HBA1 Gene Coding for Hb Charlieu (HBA1: c.320T>C) Together With β -Thalassemia Trait Results in Severe Hemolytic Anemia. *Hemoglobin*. 2019 Mar;43(2):77-82. doi: 10.1080/03630269.2019.1601107.
15. Naderi M, Cohan N, Shahramian I, Miri-Aliabad G, Haghpanah S., Karimi M. et al. A retrospective study on clinical manifestations of neonates with FXIII-A deficiency. *Blood Cells Mol Dis.* 2019 Apr 11; 77:78-81.
16. Safaei S, Abedi H, Parand S, Karimi M. Evaluation of the Effect of Support-Training System of Peer Group on Promotion of Self-Care in β -Thalassemia Major Patients in Southern Iran. *Hemoglobin*. 2019 May;43(3):198-203. doi: 10.1080/03630269.2019.1651331. Epub 2019 Aug 19.
17. Nakhost B, Nasiri M, Karimi M, Montazeri S. Down-Regulation of PU.1 Gene in Pediatric Acute Lymphoblastic Leukemia Patients from South of Iran. *International Journal of Hematology-Oncology and Stem Cell Research*. 2019 Jan; 13(1): 20-24.
18. Zahmatkeshan M Karimi M, Geramizadeh B, et al. Association between Helicobacter pylori Infection and Iron DeficiencyAnemia in School-aged Iranian Children. *Indian Pediatr.* 2019 May 15;56(5):387-389.
19. Bordbar M1, Karimi M, Shakibazad N. Thrombosis in pediatric malignancy: a review and future perspectives with focus on management. *Blood Coagul Fibrinolysis*. 2018 Nov;29(7):596-601.
20. Abdolkarimi B, Sepaskhah M, Mokhtari M, Aslani FS, Karimi M. Hypo-pigmented mycosis fungoides is a rare malignancy in pediatrics. *Dermatol Online J*. 2018 Nov 15;24(11).
21. Abolghasemi H, Panahi Y, Ahmadinejad M, Toogeh, Karimi M, et al. Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients. *J Pharmacopuncture*. 2018 Jun;21(2):76-81.
22. Haghpanah S, Zarei T, Eshghi P, Karimi M, et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. *Ann Hematol*. 2018 Oct;97(10):1919-1924.
23. Hassanzadeh J, Mirahmadizadeh A, Karimi, M, et al. Survival Rate in Thalassemia Major Patients: Difference between Date of Diagnosis and Date of Birth as an Index Date for Calculating Follow Up. *Iranian Journal of Public Health*. May 2018; 47(5): 768-769.
24. NickAria S, Haghpanah S, Ramzi M, Karimi M. Relationship of the Interaction Between Two Quantitative Trait Loci with γ -Globin Expression in β -Thalassemia Intermedia Patients. *Hemoglobin*. 2018 Mar;4741474417414102(2):108-112.
25. Haghpanah S, Jelodari S, Karamifar H, Karimi M, et al. The frequency of hypothyroidism and its relationship with HCV positivity in patients with thalassemia major in southern Iran. *Acta Biomed*. 2018 Mar 27;89(1):55-60.
26. Karimi M, Bordbar M, Aali M, Bazrafshan A, et al. Successful delivery in an patient with afibrinogenemia after three abortions: A case report and review of the literature. *Haemophilia*. 2018 Mar;24(2):e63-e66.
27. Karimi M, Eshghi P, Safarpour MM, Haghpanah S. Modified Primary Prophylaxis in Previously Untreated Patients With Severe Hemophilia A in Iran. *J Pediatr Hematol Oncol*. 2018 Apr;40(3):188-191
28. Spena S, Garagiola I, Cannavò A2, Karimi M, et al; SIPPET Study Group. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. *J Thromb Haemost*. 2018 Apr;16(4):778-790.

29. Ross C, Rangarajan S, Karimi M, Toogeh GH, et al. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. *J Thromb Haemost*. 2018 Feb;16(2):253-261.
30. Abdolkarimi B, Zareifar S, Karimi M, et al. Management of Refractory/Relapsed Acute Leukemia with Heart Limitation by Anthracycline-free Chemotherapy Regimens in Pediatric Patients: New Hypothesis and New Approach. *Middle East Journal of Cancer*; April 2018; 9(2): 77-84.
31. Karimi M, Peyvandi F, Naderi M, Shapiro A. Factor XIII deficiency diagnosis: Challenges and tools. *Int J Lab Hematol*. 2018 Feb;40(1):3-11.
32. De Sanctis V, Soliman AT, Canatan D, Elsedfy H, Karimi M, et al. An ICET- A survey on Hypoparathyroidism in Patients with Thalassaemia Major and Intermedia: A preliminary report. *Acta Biomed*. 2018 Jan 16;88(4):435-444.
33. Lissitchkov T, Madan B, Djambas Khayat C, Karimi M, Peyvandi F, et al. Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. *Transfusion*. 2018 Feb;58(2):413-422.
34. Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR; sippet study group(Karimi M). Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPEt analysis. *J Thromb Haemost*. 2018 Jan;16(1):39-43
35. Zamani S, Borhan Haghghi A, Haghpanah S, Karimi M, Bordbar MR. Transcranial Doppler Screening in 50 Patients With Sickle Cell Hemoglobinopathies in Iran. *J Pediatr Hematol Oncol*. 2017 Oct;39(7):506-512.
36. Karimi M, Amirmoezi F, Haghpanah S, Ostad S, et al. Correlation of serum ferritin levels with hepatic MRI T2 and liver iron concentration in nontransfusion beta-thalassemia intermediate patients: A contemporary issue. *Pediatr Hematol Oncol*. 2017 Aug;34(5):292-297.
37. Ravangard R, Mirzaei Z, Keshavarz K Haghpanah S, Karimi M. Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. *Hematology*. 2017 Nov 21:1-6. doi: 10.1080/10245332.2017.1404262. [Epub ahead of print]
38. Naderi M, Haghpanah S, Miri-Aliabad G, Tavosi H, Karimi M. A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran. *J Thromb Haemost*. 2017 Dec;15(12):2300-2305.
39. De Sanctis V, Soliman AT, Elsedfy H, Di Maio S, Canatan D, Soliman N6, Karimi M, et al. Gonadal dysfunction in adult male patients with thalassemia major: an update for clinicians caring for thalassemia. *Expert Rev Hematol*. 2017 Dec;10(12):1095-1106.
40. Hassanzadeh J, Mirahmadizadeh A, Karimi M, et al. Trends in 5-, 10-, 20-, and 30-year survival rates of beta-thalassemia patients in Southern Iran, 1995-2016: A retrospective cohort study. *Journal of Public Health Research* 2017; 6(3):153-157.
41. Safarpour MM, Haghpanah S, Meshksar A, Karimi M. Phenotype Report on Patients with Congenital Factor V Deficiency in Southern Iran: Recent Ten Years' Experience. *Turk J Haematol*. 2017 Aug 2; 34(3):250-253.
42. Haghpanah S, Vahdati S, Karimi M. Comparison of Quality of Life in Patients with β -Thalassemia Intermedia and β -Thalassemia Major in Southern Iran. *Hemoglobin*. 2017 Jul 25:1-6.
43. Erjaee A, Niknam M, Sadeghi A, Karimi M, et al. A significant breakthrough in the incidence of childhood cancers and evaluation of its risk factors in Southern Iran. *Indian Journal of Medical and Paediatric Oncology*. 2017 APR-JUN; 38(2):158-164.

44. Klei TRL, Kheradmand Kia S, Veldthuis , Beuger BM, Geissler J, Dehbozorgian J, Karimi M, et al. Residual pyruvate kinase activity in PKLR-deficient erythroid precursors of a patient suffering from severe haemolytic anaemia. *Eur J Haematol.* 2017 Jun;98(6):584-589.
45. De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, et al. β -Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. *Mediterr J Hematol Infect Dis.* 2017 Feb 20;9(1):e2017018.
46. Kavakli K, Demartis F, Karimi M, Eshghi P. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study. *Haemophilia.* 2017 Jul;23(4):575-582.
47. Tahmasbi L, Karimi M, Kafiabadi SA, Nikougoftar M, Haghpanah S, Ranjbaran R, Moghadam M. Evaluation of Plasma Platelet Microparticles in Thrombotic Thrombocytopenic Purpura. *Ann Clin Lab Sci.* 2017 Jan; 47(1):62-67.
48. Karimi M, Zarei T, Haghpanah S, Moghadam M, et al. Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β -Thalassemia Intermedia. *J Pediatr Hematol Oncol.* 2017 May; 39(4):e171-e176.
49. Cannavò A, Valsecchi C, Garagiola I2, Palla R, Mannucci PM1, Rosendaal FR, Peyvandi F,karimi m, SIPPET study group. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. *Blood.* 2017 Mar 9; 129(10):1245-1250.
50. Amoozgar H, Zeighami S, Haghpanah S, Karimi M. A comparison of heart function and arrhythmia in clinically asymptomatic patients with beta thalassemia intermedia and beta thalassemia major. *Hematology.* 2017 Jan; 22(1):25-29.
51. Karimi M, Haghigat M, Dialameh Z, Tahmasbi L, Parand S, Bardestani M. Breastfeeding as a Protective Effect Against Childhood Leukemia and Lymphoma. *Iran Red Crescent Med J.* 2016 Feb 13;18(9):e29771.
52. Naderi M, Karimi M, Hosseini MSet al. Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogamm P. *Iran J Pharm Res.* 2016 spring; 15(2):635-40.
53. Seyedifar M, Abedin FD, Hamidieh AA, Nader M, Karimi M, et al. Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran. *Int J Hematol Oncol Stem Cell Res.* 2016 Oct 1; 10(4):224-231.
54. Beheshtipoor N, Ghanavati S, Edraki M, Karimi M, Haghpanah S. Hemoaction Game: An educational Step to Improve Hemophilia Children and Nurses Self-Efficacy. *J Adv Med Educ Prof.* 2016 Oct; 4(4):206.
55. Karimi M, Avazpoor A, Haghpanah S, et al. Evaluation of proteinuria in B-thalassemia major patients with and without diabetes mellitus taking Deferasirox. *J Pediatr Hematol Oncol.* 2017 Jan;39(1):e11-e
56. Zarei T, Dehbozorgian J, Imanifard J, Setoodegan F, Karimi M. A Number of Cases in Iran Presenting with Coinheritance of Hb H Disease and β -Thalassemia Minor. *Hemoglobin.* 2016 Sep;40(5):316-318
57. Napolitano M, Di Minno MN, Batorova A, Dolce A, Karimi M, Mariani G, et al. Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies. *Haemophilia.* 2016 Sep;22(5):752-9.

58. Karimi M, Abdulkarimi B, Naderi M, Parand S. Aquired Hemophilia: A report of 4 cases. *Ann Hematol Oncol.* 2016; 3(1): 1074.
59. Haghpanah S, Mohtadi H, Akbari M, Karimi M. Quality of Life in Children and Adolescents with Rare Bleeding Disorders in Southern Iran. *Clin Appl Thromb Hemost.* 2016 Feb 22. pii: 1076029616634887. [Epub ahead of print]
60. De Sanctis V, Soliman AT, Elsedfy H, Albu A, Al Jaouni S5, El Kholy M, Karimi M, et al. The ICET-A Survey on Current Criteria Used by Clinicians for the Assessment of Central Adrenal Insufficiency in Thalassemia: Analysis of Results and Recommendations. *Mediterr J Hematol Infect Dis.* 2016 Jul 1;8(1):e2016034.
61. Peyvandi F, Mannucci PM, Garagiola I, Eshghi P, Karimi M, et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. *N Engl J Med.* 2016 May 26;374(21):2054-64.
62. Zarei T, Haghpanah S, Parand S, Karimi M, et al. Evaluation of bone mineral density in patients with hemoglobin H disease. *Ann Hematol.* 2016 Aug; 95(8):1329-32.
63. Karimi M, Haghpanah S, Pishdad P, Rachmilewitz EA. Frequency of silent cerebral ischemia in patients with transfusion-dependent β-thalassemia major compared to healthy individuals. *Ann Hematol.* 2016 Aug; 95(8):1387.
64. Karimi M, Jooya P, Haghpanah S, et al. Evaluation of the Relationship Between Hb F Levels and Nucleated Red Blood Cells with Morbidity in Non Transfusion-Dependent Thalassemia Patients. *Hemoglobin.* 2016 Aug; 40(4):250-6.
65. De Sanctis V, Elsedfy H, Soliman AT, Elhakim IZ, Soliman NA, Karimi M, Elalaily R. The Diagnostic Approach to Central Adrenocortical Insufficiency (CAI) in Thalassemia. *Mediterr J Hematol Infect Dis.* 2016 May 1; 8(1):e2016026.
66. Shahriari M, Bazrafshan A, Moghadam M, Karimi M. Severe hemophilia in a girl infant with mosaic Turner syndrome and persistent hyperplastic primary vitreous. *Blood Coagul Fibrinolysis.* 2016 Apr; 27(3):352-3
67. Karimi M, Tavoosi H, Haghpanah S, Ardeshtiri R, et al. Efficacy and safety of factor eight inhibitor bypassing activity prophylaxis evaluation in young patients with hemophilia and high titer inhibitor. *Blood Coagul Fibrinolysis.* 2016 Mar; 27(2):232-3.
68. Karimi M, Toosi F, Haghpanah S, et al. The frequency of silent cerebral ischemia in patients with transfusion-dependent β-thalassemia major. *Ann Hematol. Ann Hematol.* 2016 Jan; 95(1):135-9.
69. Moghadam M, Karimi M, Dehghani SJ, Dehbozorgian, et al. Effectiveness of β-thalassemia prenatal diagnosis in Southern Iran: a cohort study. *Prenat Diagn.* 2015 Dec; 35(12):1238-42.
70. Tasbihi M, Pishadad P, Haghpanah S, Ardeshtiri R, Tavoosi H, Karimi M. A comparison between MRI, sonography and Functional Independence Score in Haemophilia methods in diagnosis, evaluation and classification of arthropathy in severe haemophilia A and B. *Blood Coagul Fibrinolysis.* 2016 Mar; 27(2):131-5.
71. Haghpanah S, Bazrafshan A, Karimi M, et al. Evaluation of Thrombin Generation Assay in Patients with Hemophilia. *Clin Appl Thromb Hemost.* 2016 May;22(4):322-6.
72. Beheshtipour N, Nasirpour P, Yektatalab S, Karimi M, Zare N. The Effect of Educational-Spiritual Intervention on the Burnout of the Parents of School Age Children with Cancer: A Randomized Controlled Clinical Trial. *Int J Community Based Nurs Midwifery.* 2016 Jan; 4(1):90-7.
73. Rahimi R, Foroughi AA, Haghpanah S, Bahmanyar M, Jelodari S, De Sanctis V, Karimi M. Incidence of testicular microlithiasis in patients with β-thalassemia major. *Ann Hematol.* 2015 Nov; 94(11):1785-9.

74. Napolitano M, Dolce A, Batorova A, Karimi M, et al. Replacement therapy in inherited factor VII deficiency: occurrence of adverse events and relation with surgery. *Haemophilia*. 2015 Nov; 21(6):e513-7.
75. Geramizadeh B, Khademi B, Karimi M, Shekarkhar G. Infantile fibrosarcoma of ethmoid sinus, misdiagnosed as an adenoid in a 5-year-old child. *J Oral Maxillofac Pathol*. 2015 May-Aug; 19(2):271.
76. Bordbar MR, Bazrafshan A, Karimi M. Successful Management of Vinblastin Overdose with Exchange Transfusion: A Case Report. *Iran J Ped Hematol Oncol*. 2015; 5(2):113-5.
77. Haghpanah S, Esmaeilzadeh M, Karimi M, et al. Relationship Between Serum Hepcidin and Ferritin Levels in Patients With Thalassemia Major and Intermedia in Southern Iran. *Iranian Red Crescent Medical Journal*. 2015 Jul 7(7): e28343.
78. Karimi M, Arandi N, Haghpanah S, Ansari S, Azarkeyvan A, Bordbar M, Safaei S. Efficacy of Deferasirox (Exjade) in Modulation of Iron Overload in Patients with b-Thalassemia Intermedia. *Hemoglobin*. 2015 Jun 26:1-3.
79. Amoozgar H, Dastgheib L, Seifi V, Karimi M. Evaluation of cardiac sequelae in patients with sickle cell anemia. *HELLENIC JOURNAL OF CARDIOLOGY*. 2015 MAY-JUN . 56 (3) 242-246
80. Beheshtipoor N, Ghanavati Sh, Edraki M, Karimi M, Haghpanah S. The Effects of Computer-based Educational Games on Self-efficacy of 8-12 Children with Hemophilia. *IJBC* 2015; 7(3): 157-162.
81. De Sanctis V, Soliman A, Elsedfy H, Karimi M, Cohan N, et al. Medical care and transition phase of thalassemia in different countries: the ICET-An experience. *Rivista Italiana di Medicina dell'Adolescenza*. 2015, Suppl. 1, 13(2):5-16
82. De Sanctis V, Soliman A, Elsedfy H, Karimi M, Cohan N, et al. De Sanctis V, Soliman A, Elsedfy H, Karimi M, Cohan N, et al. General principles of good transition care: a short review of the literature *Rivista Italiana di Medicina dell'Adolescenza*. 2015, Suppl. 1, 13(2):5-10.
83. Majd Z, Haghpanah S, Matin S, Karimi M, et al. Correlation of serum ferritin levels with heart and liver MRI and LIC in transfusion dependent thalassemia patients. *IRCMJ* 2015 Apr; 17(4): e24959.
84. Zareifar S , Karimi M , Tasbihi M , Abdolkarimi B, et al. Pleuropulmonary blastoma is a rare malignancy in young adult and childhood. *Korean Journal of Clinical Oncology* 2015; 11:28-32.
85. Karimi M, Cohan N, Parand Sh. Thalassemia and Women's Health. *Women's Health Bulletin*. 2015 July; 2(3): e29440.
86. Beheshtipoor N, Bagheri SH, Karimi M, et al. The Effect of Yoga on the Quality of Life in the Children and Adolescents with Haemophilia. *IJCBNM* Apr.2015; Vol 3, No 2
87. Karimi M, Haghpanah S. The Effects of Economic Sanctions on Disease Specific Clinical Outcomes of Patients with Thalassemia and Hemophilia in Iran. *Health Policy*. 2015 Feb; 119(2):239-43.
88. Dehbozorgian M, Moghadam M, Karimi M, Haghpanah S, et al. Distribution of α -thalassemia mutations in Iranian population. *Hematology*. 2015 Jul; 20(6):359-62.
89. Arandi N, Haghpanah S, Taher AT, Karimi M, et al. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources. *Transfus Med*. 2015 Feb; 25(1):8-12.

90. Matin S, Haghpanah S, De Sanctis V, et al. The Frequency of Adrenal Insufficiency in Adolescents and Young Adults with Thalassemia Major versus Thalassemia Intermedia in Iran. *Mediterr J Hematol Infect Dis.* 2015 Jan 1; 7(1):e2015005.
91. Karimi M, Cohan N, Pishdad P. Hydroxyurea as a first line treatment of extramedullary hematopoiesis in patients with beta thalassemia, four case reports. *Hematology.* 2015 Jan; 20(1):53-7.
92. Abolhasani Foroughi A , Ghaffari H , Haghpanah S, Karimi M, et al. Comparative Study of Radiographic and Laboratory Findings Between Beta Thalassemia Major and Beta Thalassemia Intermedia Patients With and Without Treatment by Hydroxyurea. *Iranian Red Crescent Medical Journal.* 2015 February; 17(2): e23607.
93. De Sanctis V , Al Jaouni S , Elsedfy H , Karimi M, et al. Selected Highlights of the IX International Symposium of Clinicians for Endocrinopathies in Thalassemia and Adolescent Medicine (ICET-A) on Growth, and Endocrine Complications in Thalassaemia. *Rivista Italiana di Medicina dell'Adolescenza.* 2015; 13(1):1-14.
94. De Jager T1, Pericleous L, Kokot-Kierepa M, Naderi M, Karimi M. The burden and management of FXIII deficiency. *Haemophilia.* 2014 Nov; 20(6):733-40.
95. Karimi M, Cairo A, Safarpour MM, Haghpanah S, et al. Genotype and phenotype report on patients with combined deficiency of factor V and factor VIII in Iran. *Blood Coagul Fibrinolysis.* 2014 Jun; 25(4):360-3.
96. Musallam KM, Cappellini MD, Daar S, Karimi M, et al. Serum ferritin level and morbidity risk in transfusion-independent patients with β -thalassemia intermedia: the ORIENT study. *Haematologica.* 2014 Nov; 99(11):e218-21.
97. Shahriari M, Haghpanah S, Karimi M, et al. Serum cancer antigen 15.3 concentrations in patients with beta-thalassemia minor compared to those with cancer and healthy individuals. *Med J Islam Repub Iran.* 2014 Sep 13; 28:91. ECollection 2014.
98. Pasalar M, Mehrabani D,, Karimi M. et al. Prevalence of thalassaemia, iron-deficiency anaemia and glucose-6-phosphate dehydrogenase deficiency among Arab migrating nomad children, southern Islamic Republic of Iran. *East Mediterr Health J.* 2014 Dec 17; 20(11):726-31.
99. Faranoush M, Abolghasemi H, Toogeh G, Karimi M, et al. A Comparison between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Congenital Factor VII Deficiency. *Clin Appl Thromb Hemost.* 2015 Nov; 21(8):724-8.
100. Faranoush M1, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, et al. A Comparison of Efficacy between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Hereditary FVIII Deficiency with Inhibitor. *Clin Appl Thromb Hemost.* 2014 Oct 24. [Epub ahead of print]
101. De Sanctis V, Soliman AT, Karimi M, et al. Insulin-like Growth Factor-1 (IGF-1): Demographic, Clinical and Laboratory Data in 120 Consecutive Adult Patients with Thalassaemia Major. *Mediterr J Hematol Infect Dis* 2014; 6; 1-10.
102. Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A. Guidelines for diagnosis and management of Beta-thalassemia intermedia. *Pediatr Hematol Oncol.* 2014 Oct; 31(7):583-96.
103. Haghpanah S, Ramzi M, Zakerinia M, Karimi M, et al. Epidemiology of Hemoglobinopathies and Thalassemias in Individuals Referred to the Haematology Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran From 2006 to 2011. *Hemoglobin.* 2014; 38(4):287-8.

104. Bordbar M, Haghpanah S, Karimi M, et al. Hydroxyurea treatment in transfusion dependent beta thalassemia patients. *Iran Red Crescent Med J.* 2014; 16(6):e18028
105. Khavari M, Hamidi A, Haghpanah S, et al. Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea. *Iran Red Crescent Med J.* 2014 Jul; 16(7):e18712.
106. Honar N, Karimi M. et al. Frequency of Celiac Disease in Children with Beta Thalassemia major. *Iranian Journal of Pediatric Hematology Oncology*2014; 4(2):48-52.
107. Shakibazad N , Karimi M. Rhabdomyosarcoma of Eyelid: A picture presentation. *IJBC* 2014; 6(3): 221-222.
108. Haghpanah S, Zarei T, Zahedi Z, Karimi M. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. *Hematology.* 2014 Jun; 19(4):187-91.
109. Naderi M, zarei T, Karimi M, et al. Intracranial hemorrhage pattern in the patients with Factor XIII deficiency. *Ann Hematol.* 2014 Apr; 93(4):693-7.
110. Batorova A1, Mariani G, Kavakli K, de Saez AR, Caliskan U, Karimi M,et al. Inhibitors to factor VII in congenital factor VII deficiency. *Haemophilia.* 2014 Mar; 20(2):e188-91.
111. Golafshan HA, Karimi M, Sharifzadeh S. et al. Evaluation of red cell membrane cytoskeletal disorders using a flow cytometric method in South Iran. *Turk J Hematol.* 2014 Mar; 31 (1):25-31
112. Haghpanah S, Karimi M, et al. An experience of using Traumastem P in control of spontaneous nose bleeding in patients with inherited bleeding disorders in southern Iran. *Haemophilia.* 2014 Jan; 20(1):e79-80.
113. Zekavat OR, Makarem AR, Haghpanah S, Karimi M. Hypothyroidism in β -Thalassemia Intermedia Patients with and without Hydroxyurea. *Iran J Med Sci.* 2014 Jan; 39(1):60-3.
114. De Sanctis V1, Soliman AT2, Elsedfy H3, Karimi M, et al. Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. *Pediatr Endocrinol Rev.* 2013 Dec; 11(2):167-80.
115. Parand F, Honar N, Aflaki Kh, Karimi M, et al. Management of bleeding in post-liver disease, surgery and biopsy in patients with high uncorrected international normalized ratio with prothrombin complex concentrate - an Iranian experience. *IRCMJ,* 2013 December; 15(12): e12260
116. Parand A, Karimi M, et al. Inherited Thrombophilia and Recurrent Pregnancy Loss. *IRCMJ.* 2013 Dec. 15(12): e13708
117. Keshtkaran A, Javanbakht M, Karimi M. et al. Cost-utility analysis of oral deferasirox versus infusion defereoxamine in transfusion-dependent B-thalassemia patients. *Transfusion.* 2013 Aug;53 (8):1722-9
118. Zekavat OR, Haghpanah S, Dehghani J, Afrasiabi A, Peyvandi F, Karimi M. Comparison of Thrombin Generation Assay With Conventional Coagulation Tests in Evaluation of Bleeding Risk in Patients With Rare Bleeding Disorders. *Clin Appl Thromb Hemost.* 2013 Feb 6; 20(6):637-644
119. Karimi M, Jenabali Jahromi B, De Sanctis V, et al. Prevalence of ovarian cysts in female patients with beta-thalassemia major in Fars province, South Iran. *Rivista Italiana di Medicina dell'Adolescenza.* 2013; 11(2): 61-5.

120. Zarei T, Haghpanah S, Karimi M, et al. Frequency of ovarian cyst in women with beta-thalassemia intermedia in Southern Iran. *Rivista Italiana di Medicina dell'Adolescenza*. 2013; 11(3): 35-37.
121. Soliman A., De Sanctis V., elsedfy H , Karimi M, et al. Growth hormon deficiency in adults with thalassemia: An overview and the I-CET recommendations. *Georgian Medical news*. 2013; 9 (222): 79-84.
122. Zekavat O.R., Geramizadeh B., Makarem A., Karimi M. Multiple subcutaneous nodules as a rare presentation of alveolar rhabdomyosarcoma. *Eur. J. Pediat. Dermatol.* 2013; 23, 78-82.
123. Haghpanah S, Nasirabadi S, Ghaffarpasand F, Karami R, Mahmoodi M, Parand S, Karimi M. Quality of life among Iranian patients with beta-thalassemia major is using the SF-36 questionnaire. *Sao Paulo Med J*. 2013; 131(3):166-72.
124. Naderi M, Eshghi P, Cohan N, Haghpanah S, Karimi M. Evaluation of the FXIII deficiency prophylaxis intervals in large number of FXIII deficiency patients from Iran. *Haemophilia*. 2013; 19: e174-e192
125. Bagheri S, Beheshtipoor N, Rambod M, Karimi M, Zare N, Hashemi F. The quality of life of children with hemophilia in Shiraz, Iran. *IJCBNM*. 2013; 1(2): 110-120.
126. Mariani G, Napolitano M, Dolce A, Pérez Garrido R, Batorova A, Karimi M, et al. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. *Thromb Haemost*. 2013 Feb; 109(2):238-47.
127. Haghpanah S, Karimi M. Frequency of combined factor V and factor VIII deficiency in southern Iran. *Blood Coagul Fibrinolysis*. 2013; 24(4):458-9.
128. Saki F., Bordbar MR, Karimi M, et al. Diffuse Hepatic Calcifications in a Transfusion-Dependent Patient with Beta-Thalassemia: A Case Report. *Iran J Med Sci Sep*. 2013; 38 (3):271-74.
129. Haghpanah S, Ardeshiri R, Zahedi Z, Karimi M, et al. Attitudes and practices with regard to circumcision in haemophilia patients in Southern Iran. *Haemophilia*. 2013 May; 19(3):e177-8.
130. Tabei SM, Mazloom M, Shahriari M, Zareifar S, Azimi A, Hadaegh A, Karimi M. Determining and Surveying the Role of Carnitine and Folic Acid to Decrease Fatigue in β-Thalassemia Minor Subjects. *Pediatr Hematol Oncol*. 2013 Nov; 30(8):742-7.
131. Bordbar MR., Zareifars S, Karimi M, et al. Unusual Presentation of T-cell non-Hodgkin Lymphoma with Multiple Skin Nodules. *IJBC* 2013; 4: 179-181
132. Hashemi F, Sedghi M, Karimi M. The impact of educating parents of leukaemic children on the healthy siblings' quality of life. *Journal of the Pakistan medical assosciation*. 2013; 63(2): 249-252.
133. Shariat A , Nazeri M, Karimi M, et al. Transcranial Doppler Ultrasonography in Beta-thalassemia Major Patients Without and With Thrombocytosis. *Iran Red Crescent Med J*. 2013; 15(3).
134. Saffari B, Senemar S, Karimi M, et al. An MTHFR Variant, Plasma Homocysteine Levels and Late-Onset Coronary Artery Disease in Subjects from Southern Iran. *Pakistan Journal of Biological Sciences*. 2013; 16(16): 788-795.
135. Hamidian Jahromi A, Karimi M. DDAVP might reduce the risk of preeclampsia in pregnant women with VWF deficiency. *Turk J Hematol* 2013; 30: 214-215
136. Haghpanah S, Karimi M, Bordbar M, Kamfiroozi R, Asgharzadeh H. Experience on Using Prothrombin Complex Concentrate in Urgent Warfarin Reversal: An Iranian Survey. *Clin Appl Thromb Hemost*. 2013 Jun; 19(3):277-81

137. Haghpanah S, Johari S, Parand S, Bordbar MR, Karimi M. Family Planning Practices in Families with Children Affected by β -Thalassemia Major in Southern Iran. *Hemoglobin*. 2013; 37(1): 74–79.
138. Karimi M, Haghpanah S, Ashjazadeh N. Cerebral Artery Velocity Determined by Transcranial Doppler Ultrasonography in Patients With β -Thalassemia Intermedia Compared to β -Thalassemia Major. *Clin Appl Thromb Hemost*. 2013 Jul; 19(4):367-73.
139. Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in β -thalassemia intermedia: Breaking the silence. *Thromb Res*. 2012; 130: 695–70.
140. Van Geffen M, Menegatti M, Loof A, Lap P, Karimi M, et al. Retrospective evaluation of bleeding tendency and simultaneous thrombin and plasmin generation in patients with rare bleeding disorders. *Haemophilia*. 2012 Jul; 18(4):630-8.
141. Karimi M, Haghpanah S, Taher AT, Cappellini MD. B-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life. *Anemia*. 2012:902067.
142. Karimi M, Haghpanah S, Bagheri MH, et al. Frequency and distribution of asymptomatic brain lesions in patients with beta-thalassemia intermedia. *Ann Hematol*. 2012; 91:1833–1838.
143. Karimi M, Azarkeivan A, Zareifar S, et al. Iranian experience of deferasirox (Exjade®) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels? *Hematology* 2012; 17 (6):367-71.
144. Haghpanah S, Nasirabadi S, Rahimi N, Faramarzi H, Karimi M. Sociocultural challenges of beta-thalassaemia major birth in carriers of beta-thalassaemia in Iran. *J Med Screen*. 2012; 19(3):109-11.
145. Bordbar MR, Taj-Aldini R, Haghpanah S, Karimi M, et al. Thyroid function and stress hormones in children with stress hyperglycemia. *Endocrine*. 2012 Dec; 42(3):653-7.
146. Ashjazadeh N, Emami S, Petramfar P, Yaghoubi E, Karimi M. Intracranial Blood Flow Velocity in Patients with β -Thalassemia Intermedia Using Transcranial Doppler Sonography: A Case-Control Study. *Anemia*. 2012:798296.
147. Naderi M, Eshghi P, Cohan N, Karimi M et al. Successful delivery in patients with FXIII deficiency receiving prophylaxis: report of 17 cases in Iran. *Haemophilia*. 2012 Sep; 18(5):773-776.
148. Karimi M, Emad Marvasti V , Karamifar H, et al. Prevalence of gynecomastia in blood transfusion beta thalassemia major adolescent boys. *Rivista Italiana di Medicina dell'Adolescenza*. 2012; 10(3): 101-4
149. Karimi M, Marvasti VE, et al. Prevalence of Delta Beta Thalassemia Minor in Southern Iran. *IJBC* 2012; 4: 153-155.
150. Bazrgar M, Karimi M. Is the apolipoprotein E4 allele always hazardous? Serum uric acid level as a conflict. *Genet Test Mol Biomarkers*. 2012 Aug; 16(8):920-3.
151. Haghpanah S, Nasirabadi Sh, Karimi M, et al. Polymorphisms Associated with Sickle Cell Disease in Southern Iran. *Russian Journal of Genetics*. 2012; 48:755–757.
152. Taher AT, Musallam KM, Karimi M, Cappellini MD. Contemporary approaches to treatment of beta-thalassemia intermedia. *Blood Rev*. 2012 Apr; 26 Suppl 1:S24-7.
153. Bordbar M, Haghpanah S, Afrasiabi A, Dehbozorgian J, Karimi M. Genotype-phenotype correlation related to lipid profile in beta-thalassemia major and intermedia in southern Iran. *J Clin Lipidol*. 2012 Mar; 6(2):108-13.

154. Karimi M, Zekavat OR, Haghpanah S, Javad P, Karamizadeh Z. Comparative study of hypogonadism in beta-thalassemia intermedia patients with and without hydroxyurea. *Hematology*. 2012 Mar; 17(2):122-4.
155. De Sanctis V, Elawwa A, Angastiniotis M, Eleftheriou A, Kattamis C, Karimi M, El Kholy M, Elsedfy H, Yassin MA, Fiscina B, Soliman AT. Highlights from the First Thalassaemia Forum on Growth and Endocrine Complications in Thalassemia Doha, (October 2-3, 2011). *Pediatr Endocrinol Rev*. 2012 Mar; 9(3):672-9.
156. Mehramiri A, Parand S, Haghpanah S, Karimi M. Attitudes of haemophilic patients towards their health and socio-economic problems in Iran. *Haemophilia*. 2012 Jan; 18(1):122-8.
157. Rashid M, Karimi M. Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran. *Transfus Med*. 2012 Apr; 22(2):104-7
158. Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotype-phenotype relationship of patients with β -thalassemia taking hydroxyurea: a 13-year experience in Iran. *Int J Hematol*. 2012 Jan; 95(1):51-6.
159. Karimi M. Hydroxyurea therapy in thalassemia. *TIF magazine*. 2012
160. Eshghi P, Cohan N, Lak M, Naderi M, Peyvandi F, Menegatti M, Karimi M. Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran. *Clin Appl Thromb Hemost*. 2012 Jan-Feb; 18(1):100-3.
161. Haghpanah S, Karimi M. Cerebral thrombosis in patients with β -thalassemia: a systematic review. *Blood Coagul Fibrinolysis*. 2012 Apr; 23(3):212-7.
162. Dehghani SJ, Amiri Dashtarzhen A, Karimi M, et al. Combined α -thalassemia and Hemoglobin J-Iran (β 77 His \rightarrow Asp). A Family Study in southern Iran. *Iran Red Crescent Med J*. 2011 Aug; 13(8):586-9.
163. De Sanctis V, Soliman AT, Angastiniotis M, Eleftheriou A, Kattamis Ch, Karimi M, et al. International network on endocrine complications in thalassaemia (I-CET): an opportunity to grow. *Georgian Med News*. 2012 Apr ;(205):52-7.
164. Karimi M, Vafafar A, Haghpanah S, et al. Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran. *Haemophilia*. 2012 Mar; 18(2):2011-215.
165. Bastani P, Pourmohamadi K, Karimi M. Quality of life in hemophilia complicated by inhibitors. *Iran Red Crescent Med J*. 2012 Apr; 14(4):250-1.
166. Karimi M, Emadmarvasti V, Hoseini J, Shoja L. Major Causes of Hospital Admission in Beta Thalassemia Major Patients in Southern Iran. *IJP*. 2011; 21(4): 509-513.
167. Cohan N, Karimi M. Diagnosis and Management of von Willebrand Disease in Iran. *SEMIN THROMB HEMOST*. 2011; (5):602-13.
168. Karimi M & Cohan N. B-thalassemia Intermedia, a review of literature. *IJBC*. 2011; 4:179-187.
169. Rasekh HR, Imani A, Karimi M, Golestani M. Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran. *Clinicoecon Outcomes Res*. 2011; 3:207-12.
170. Kiadaliri A, Bastani P, Karimi M, et al. The Impact of Factor VIII Inhibitors on Factor Consumption in Haemophilia A: A Case-Control Study in South of Iran. *Middle East Journal of Scientific Research*. 2011; 8(3): 694-98.

171. Karimi M, Musallam Kh, Cappellini M, taher A, et al. Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. European Journal of Internal Medicine. 2011; 22: 607–610.
172. Pishva N, Afrasiabi A, Shahbazi MR, Karimi M, Haghpanah S. Protein C concentration in newborn infants with sepsis-like illness. Journal of Neonatal-Perinatal Medicine 4 (2011) 55–58.
173. Hashemi F, Asadi N, Beheshtipour N, Karimi M. The Impact of Educating Parents of Leukemic Children on the Patients' Quality of Life. Iran Red Crescent Med J. 2011; 13(8):553-7.
174. Basiratnia M, Yavarian M, Karimi M, et al. Non-Hodgkin Lymphoma in a Child with Schimke Immuno-Osseous Dysplasia. Iran J Med Sci September 2011; 36
175. Amoozgar H, Farhani N, Karimi M. Risk factors for pulmonary hypertension in patients with thalassemia intermedia. European Journal of Haematology. 2011; 85:549-551
176. Karimi M, Ravanbod S, Cohan N, Ala F. How to deal with medical and social aspects of bleeding disorders--preparing women and the family in developing countries. Haemophilia. 2011 Jul; 17 Suppl 1:42-4.
177. Haghpanah S, Vafafar M, Karimi M, et al. Use of Glubran 2 and Glubran tissue skin adhesive in patients with hereditary bleeding disorders undergoing circumcision and dental extraction. Ann Hematol. 2011; 90:463-468.
178. Amoozgar H, Farhani N, Khodadadi N, Karimi M, Cheriki S. Comparative study of pulmonary circulation and myocardial function in patients with β -thalassemia intermedia with and without hydroxyurea, a case-control study. Eur J Haematol. 2011 Jul; 87(1):61-7.
179. Amoozgar H, Farhani N, Karimi M. Early echocardiographic findings in β -thalassemia intermedia patients using standard and tissue Doppler methods. Pediatr Cardiol. 2011; 32:154-159.
180. Cohan N, Sarikhani S, Moslemi S, Karimi M. Initial presentation of acute lymphoblastic leukemia with osteoporosis and multiple spontaneous bone fractures. Iran Red Crescent Med J 2011;13(1):52-54
181. Karimi M, Emad Marvasti V, Imanieh MH, Jahaniar Moqadam F. Amantadine plus interreron- α versus interferon- α monotherapy for the treatment of chronic hepatitis C infection in β -thalassemia major patients: a randomized double blinded pilot study in Shiraz, Iran. Iranian Journal of Blood and Cancer Vol 2 No 1 Autumn 2009, 19-23
182. Shamsakhzari Sh, Afrasiabi AB, Haghpanah S, Karimi M. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease in southern Iran. Blood Coagul Fibrinolysis. 2011 Jun; 22(4):325-30.
183. Jenabali Jahromi B, Karimi M. Long-term follow-up of prophylaxis with recombinant activated factor VII in patients with congenital factor VII deficiency. Haemophilia 2011; 17, 703–20.
184. Rezaeifarid M, Soveid M, Ghaemi S, Karimi M. Bone mineral density in Iranian patients with hemophilia: the first experience in southern Iran. Haemophilia. 2011 May; 17(3):552-3.
185. Haghpanah S, Sahraiian M, Afrasiabi A.R, Enayati S, Karimi M. The correlation between gene mutations and inhibitor development in patients with hemophilia A in southern Iran. Haemophilia 2011; 17:815-829.
186. Rezazadeh S, Haghigat A, Mahmoodi M, Babanezhad Z, Karimi M. Synoviorthesis induced by Rifampicin in hemophilic arthropathy; Report of 24 treated joints. Annals of Hematology. 2011, 90:963–969.

187. Alyasin S, Moghtaderi M, Karimi M, et al. Pulmonary function test in transfusion-dependent β -thalassemia major patients: a pilot study. *Pediatr Hematol Oncol.* 2011 May; 28(4):329-33.
188. Yavarian M, Cohan N, Karimi M, et al. Impact of Iron deficiency anaemia on HbA2 levels. *Journal of Applied Hematology.* 2011; 200-2.
189. Mahmoodi M, Peyvandi F, Afrasiabi A.R, Ghaffarpasand F, Karimi M. Bleeding Symptoms in Heterozygous Carriers of Inherited Coagulation Disorders in Southern Iran. *Blood Coagulation and Fibrinolysis.* 2011, Vol 22 No 5.
190. Yavarian M, Ramzi M, Karimi M, et al. Impact of inherited thrombophilic factors on deep vein thrombosis in individuals in south Iran. *Journal of Applied Hematology* 2011, 15-19.
191. Mahdavi MR, Karimi M, Yavarian M, et al. Detection of Hb Setif in north Iran and the question of its origin: Iranian or multiethnic? *Hemoglobin.* 2011;35(2):152-6.
192. Hassanzadeh J, Mohammadi R, Rajaeefard A.R, Bordbar M.R, Karimi M. Maternal and Prenatal Risk Factors for Childhood Leukemia in Southern of Iran. *IRCMJ* 2011; 13(6):1-6.
193. Mahmoodi M, De Sanctis V, Karimi M. Diffuse Intracerebral Calcification in a Beta-Thalassaemia Major Patient with Hypoparathyroidism: A Case Report. *Pediatric Endocrinology Reviews* 2011; 8 (Sup 2):331-3.
194. Amooee S, Samsami A, Jahanbakhsh J, Karimi M. The pregnancy outcome in patients with minor beta-thalassemia. *IJRM* 2011; 9(1): 9-14.
195. De Sanctis V, Giovannini M, Ciccone S, Karimi M. Generalized Tonic-Clonic Seizure in a Thalassemic Patient with Hypoparathyroidism and Brain Calcinosis. *Pediatric Endocrinology Reviews* 2011; 8(sup 2):334-6.
196. Mahjour SB, Ghaffarpasand F, Fattahi MJ, Ghaderi A, Fotouhi Ghiam A, Karimi M. Seroprevalence of human herpes simplex, hepatitis B and epstein-barr viruses in children with acute lymphoblastic leukemia in Southern Iran. *Pathol. Oncol. Res.* (2010) 16:579-582
198. Bazrgar M, Peiravian F, Abedpour F, Karimi M. Causes for hospitalization and death in Iranian patients with β -thalassemia major. *Pediatr Hematol Oncol.* 2011 Mar; 28(2):134-9.
199. Shahriari M, Bordbar M.R, Geramizadeh B, Karimi M. Leukemic infiltration of the appendix as an unusual site of extramedullary relapse: report of two cases and review of the literature. *IJMS* Vol 35, Sep. 2010
200. Karimi M, Mehrabani D, Pasalar M, Afrasiabi AR, Mehravar Z, et al. Thalassemia, iron and G6PD deficiency in lor migrating nomad children, Southern Iran. *IRCMJ* 2010;12(4):441-445
201. De Sanctis V, Ciccone S, Karimi M. Generalized tonic-clonic seizures in a thalassemic patient with hypoparathyroidism and brain calcinosis. *Rivista Italiana di Medicina dell' Adolescenza - Volume 8, n. 2, 2010*
202. Faramarzi A, Karimi M, Heydari S.T, et al. Frequency of sensory neural hearing loss in major beta-thalassemias in Southern Iran. *Iran J Pediatr*, Sep 2010;Vol 20 (No 3), 308-312
203. Karimi M, Khanlari M, Rachmilewits EA. Erratum: "Cerebrovascular accident in β -thalassemia major (β -TM) and β -thalassemia intermedia (β -TI)" by Karimi et al. *Am J Hematol* 83:77-79, 2008, DOI number 20938. *Am J Hematol.* 2010 Sep 14.
204. Taher AT, Masullam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. *J Thromb Haemost.* 2010; Jun 7.
205. Taher AT, Musallam KM, El-Beshlawy A, Karimi M, et al. Age-related complications in treatment-naïve patients with thalassemia intermedia. *Br J Haematol.* 2010 Aug; 150(4):486-9.

206. Haghpanah S, Davani M, Samadi B, Ashrafi A, Karimi M. Serum lipid profiles in patients with beta-thalassemia major and intermedia in southern Iran. JRMS/May & June 2010; Vol 15, No 3
207. Karimi M, Emad Marvasti V, Rasekhi A, et al. MRI evaluation of liver iron concentration in patients with β-thalassemia major. Hepatitis Monthly 2010; 10(2):149-150.
208. Karimi M, Cohan N. Cancer-associated thrombosis. The Open Cardiovascular Medicine Journal, 2010, 4, 59-63.
209. Karimi M, Bagheri H, Rastgu F, et al. Magnetic resonance imaging to determine the incidence of brain ischemia in patients with β-thalassemia intermedia. Thrombosis and Haemostasis 103.5/2010
210. Akbari A, Dehbozorgian J, Afrasiabi A.R., Safari H, Gerdabi J, Karimi M. Frequency of afterload homocysteine in normal population of southern Iran: A pilot study. Pakistan Journal of Biological Sciences 13(7):352-354,2010
211. Zareifar S, Bordbar MR, Karimi M, Geramizadeh B, Rasekhi AR. T-cell lymphoblastic lymphoma of the sternum. J Clin Oncol. 2010 Feb 1; 28(4):e51-3.
212. Fotouhi Ghiam A, Hashemi A, Taban S, Bordbar M.R, Karimi M. Beta thalassemia minor as a risk factor for suicide and violence: A failure to replicate. Pshychology, 2010,1:17-21
213. Eshghi P, Mahdavi M, Karimi M, Aghighi M. Haemophilia in the developing countries: the Iranian experience. Arch Med Sci 2010; 6, 1: 83-89.
214. Karimi M, Johari S, Cohan N. Attitude toward prenatal diagnosis for beta-thalassemia major and medical abortion in Southern Iran. Hemoglobin. 2010; 34(1):49-54.
215. Karimi M, Cohan N, Moosavizadeh K, Falahi MJ, Haghpanah S. Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience. Pediatr Hematol Oncol. 2010 Apr; 27(3):205-11.
216. Karimi M, Haghpanah S, Amirkhani A, Afrasiabi AR, et al. Spectrum of inherited bleeding disorders in southern Iran, before and after the establishment of comprehensive coagulation laboratory. Blood Coagulation and Fibrinolysis 2009,20:642-645
217. Karimi M. Hydroxyurea in the management of thalassemia intermedia. Hemoglobin. 2009; 33 Suppl 1:S177-82.
218. Karimi M, Afrasiabi A, Amoei S, et al. Goagulation disorder in women with idiopathic menorrhagia. APJOH 2010; 2(1), February.
219. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication-rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2009 Dec 23.
220. Rashid M, Majid OB, Dehghani M, Karimi M. Normal hemoglobin and hematological indices in Southwest of Iran. IJBC Vol 1, No 3, Spring 2009, 99-101.
221. Yavarian M, Shahian M, Karimi M, Rezaie N. Prevalence of pyruvate kinase deficiency among the newborns (Shiraz-Iran). IJBC Vol 1, No 3, Spring 2009, 89-93.
222. Yavarian M, Karimi M, Paran F, et al. Multi centric origin of Hb D-Punjab [beta 121 (CH4) Glu--> Gln, GAA>CAA]. Hemoglobin. 2009, 33(6):399-405.
223. Eshghi P, Mahjour SB, Naderi M, Dehbozorgian J, Karimi M. Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran. Haemophilia. 2010,16(2):38

224. Yavarian M, Saberfiroozi M, Mehrabani D, Amirizadeh S, Karimi M. Prevalence of the HFE gene mutation in the liver transplanted and primary hemochromatosis patients in the Southern Iran. *IRCMJ* 2010; 12(1):22-26.
225. Zekavat OR, Mohammadi Samani S, Nasibi S, Karimi M. Clinical evaluation of the new topical anesthetic formulation in β-thalassemia major patients. *The Journal of Applied Research* Vol. 9, No. 3, 2009.
226. Karimi M, Cohan N, Zareifar S, et al. Initial presentation of childhood leukemia with facial palsy: three case reports. *BMJcasereports* 2009; Dec.
227. Taban S, Fotouhi Ghiam A, Mosallaei A, Bordbar MR, Mannucci PM, Karimi M. Frequency of antiphospholipid antibodies in Iranian patients with solid malignancies: a pilot study. *Iran J Immunol.* 2009 Sep; 6(3):160-2.
228. Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S. Effect of combination therapy of hydroxyurea with L- carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. *Eur J Haematol.* 2010 Jan 1; 84(1):52-8.
229. Roozbeh J, Sharifian M, Karimi M, Hamidian Jahromi AR, Afshariani R. Effect of zinc supplementation on red blood cell osmotic fragility in hemodialysis patients. *Shiraz E Medical Journal.* 2009 Oct; Vol. 10, No. 4
230. Lotfi M, Keramati P, Assdsangabi R, Nabavizadeh SA, Karimi M. Ultrasonographic assessment of the prevalence of cholelithiasis and biliary sludge in beta-thalassemia patients in Iran. *Med Sci Monit.* 2009 Aug;15(8):CR398-402
231. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. *Semin Thromb hemost.* 2009 Jun;35(4):426-38
232. Geramizadeh B, Banani A, Foroutan H, Aminsharifi A, Karimi M. Malignant epithelioid hemangioendothelioma of the bladder: the first case report in a child. *J Pediatr Surg.* 2009 Jul;44(7):1443-5
233. Karimi M, Giti R, Haghpanah S, Azarkeivan A, Hoofar H, Eslami M. Malignancies in patients with beta-thalassemia major and beta-thalassemia intermedia: A multicenter study in Iran. *Pediatr Blood Cacer.* 2009, Dec.
234. Beheshtipour N, Cohan N, Karimi M. Home therapy and the effect of educational programmes in Iran; an alternative treatment option in developing countries. *Haemophilia.* 2009 May 19.
235. Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. *Fundam Clin Pharmacol.* 2009 Jun; 23(3):359-65.
236. Mehrabani D, Pasalar M, Afrasiabi A.R, Mehravar Z, Reyhani I, Hamidi R, Karimi M. Frequency of thalassemia, Iron and Glucose-6-phosphate dehydrogenase deficiency among Turkish migrating nomad children in southern Iran. *Acta Medica Iranica.* 2009;Vol 47, No.1, 20-24
237. Zekavat OR, Karimi M, Rahamanian F. Is red cell from an otherwise healthy G6PD-deficient donor efficient for transfusion to favism patients? *Indian J Hematol Blood Transfus.* 2009 March;25(1):23-26
238. Rasekhi AR, Naderifar M, Bagheri MH, Shahriari M, Foroutan H, Karimi M, et al. Radiofrequency ablation of the spleen in patients with thalassemia intermedia: a pilot study. *AJR Am J Roentgenol.* 2009 May; 192(5):1425-9

239. Palla R, Lavoretano S, Lombardi R, Garagiola I, Karimi M, et al. The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. *Haematologica*. 2009 Feb;94(2):289-93
240. Karimi M, Rasekhi AR, Rasekh M, Nabavizadeh SA, Assadsangabi R, Amirkhani GH. Hypoparathyroidism and intracerebral calcification in patients with beta-thalassemia major. *Eur J Radiol*. 2009 Jun; 70(3):481-4.
241. Karimi M, Haghigat M, Moemen T, Jamalian N. Prevalence of Helicobacter pylori - associated peptic lesions among patients with sickle cell disease with recurrent abdominal pain. *Indian J Gastroenterol*. 2008 Sep-Oct; 27(5):213-4.
242. Karimi M, Bonyadi M, Galehdari MR, Zareifar S. Termination of pregnancy due to Thalassemia major, Hemophilia, and Down's syndrome: the views of Iranian physicians. *BMC Med Ethics*. 2008 Dec 23; 9(1):19.
243. Karimi M, Borzouee M, Mehrabani A, Cohan N. Echocardiographic finding in beta-thalassemia intermedia and major: Absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. *Eur J Haematol*. 2008 Dec 5.
244. Jafari H, Lahsaeizadeh S, Jafari P, Karimi M. Quality of life in thalassemia major: reliability and validity of the Persian version of the SF-36 questionnaire. *J Postgrad Med*. 2008 Oct-Dec;54(4):273-5
245. Karimi M, Cohan N, Bagheri MH, Lotfi M, Omidvari Sh, Gramizdeh B. A lump on the head. *Lancet*. 2008 Oct 18; 372(9647):1436.
246. Gharagozloo M, Karimi M, Amirghofran Z. Double-faced cell-mediated immunity in beta-thalassemia major: Stimulated phenotype versus suppressed activity. *Ann Hematol*. 2009 Jan; 88(1):21-7.
247. Karamifar H, Karimi M, Sobhani N. Insulin-like growth factor-1 levels in children with Beta-thalassemia minor. *Turk J Haematol*. 2008 Sep.; 25 (3): 136-139
248. Karimi M, Jafari H, Lahsaeizadeh S, Afrasiabi A, Akbari A, Dehbozorgian J, Ardestiri R, et al. Factor XI deficiency in Southern Iran: identification of a novel missense mutation. *Annals of Hematology* 2009; 88 (4): 359-363
249. Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani M.T, Chung D.W, Ferrari S, Fujimura Y, Karimi M, et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). *Journal of Thrombosis and Hemostasis*, 2008 (6): 1534-1541
250. Karimi M, Mehrabani D, Yarmohammadi H, Safaei Jahromi F. The prevalence of signs and symptoms of childhood leukemia and lymphoma in Fars Province, Southern Iran. *Cancer Detect Prev*. 2008; 32(2):178-83.
251. Karimi M. Successful control of central nervous system bleeding in two newborns with severe factor VII deficiency using rFVIIa administered via Port-a-Cath. *Semin Hematol*. 2008; 45 (SUPPL. 1): S74
252. Karimi M, Karamizadeh Z, Lahsaeizadeh S, Jafari H, Mavali Y, De Sanctis V. Prevalence of diabetic ketoacidosis (DKA) in thalassemia major patients in Iran due to secondary iron overload. *Rivista Italiana di Medicina dell' Adolescenza – Volume 6, n. 1, April 2008*, 47-51.
253. Karimi M, Lahsaeizadeh S, Jafari H, Salami Z. Evaluation of prevalence of drug dependence in beta-thalassemic patients and its risk factors. *Journal of substance Use*. 2008; 13 (5): 293-298

254. Karimi M, Borhani Haghghi A, Yazdani M, Raisi H, Giti R, Namazee MR. Is β -thalassemia trait a protective factor against ischemic, cerebrovascular accidents? Journal of stroke and cerebrovascular diseases, Vol 17, No. 2,(March-April), 2008: 79-81
255. Karimi M, Menegatti M, Afrasiabi A, Sarikhani S, Peyvandi F. Phenotype and genotype report on homozygous and heterozygous patients with congenital Factor X deficiency. Haematologica. 2008; Haematologica 93 (6): 934-938
256. Karimi M, Shafieian R. Prophylactic effect of recombinant factor VIIa in two patients with congenital factor VII deficiency. Haemophilia. 2008 Jul; 14(4):851-2.
257. Karimi M, Rahmani S, Ardestiri R, Pasalar M. Health status in Iranian haemophilic patients. Haemophilia. 2008; Haemophilia 14 (3): 615-617
258. Karimi M, Jamalian N. Sociocultural challenges of thalassemia birth in Islamic and developing countries. J Pediatr Hematol Oncol, 2008 Apr; 30(4):335.
259. Derakhshan A, Karimi M, Ghadimi Moghadam A. Comparative evaluation of renal findings in Beta-thalassemia major and intermedia. Saudi J Kedney Dis Transpl 2008; 19(2):206-209.
260. Kashef S, Karimi M, Amirghofran Z, Ayatollahi M, et al. Antiphospholipid antibodies and hepatitis C virus infection in Iranian thalassemia major patients. Int. Jnl. Lab. Hem. 2008; 30: 11-16.
261. Peyvandi F, Lavoretano S, Palla R, Feys H.B, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani M.T, Fabris F, Zver S, Reti M, Mikovic D, Karimi M, et al. Adamts13 and anti-adamts13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008 Feb;93(2):232-9
262. Karimi M, Yavarian M, Afrasiabi A, Dehbozorgian J, Rachmilewitz E. Prevalence of beta-Thalassemia Trait and Glucose-6-Phosphate Dehydrogenase Deficiency in Iranian Jews. Arch Med Res. 2008 Feb; 39(2):212-4.
263. Inaloo S, Karimi M. Facial palsy as first presentation of acute lymphoblastic leukemia: A case report. Iran J Child Neurology. 2007 Nov;2(1):51-53
264. Karimi M, Bagheri MH, Tahmtan M, Shakibafard A, Rashid M. Prevalence of hepatosplenomegaly in beta thalassemia minor subjects in Iran. 2009; European Journal of Radiology 69 (1): 120-122.
265. Yavarian M, Karimi M, Shahriary M, Afrasiabi AR. Prevalence of pyruvate kinase deficiency among the south Iranian population: Quantitative assay and molecular analysis. Blood Cells Mol Dis. 2008; Blood Cells, Molecules, and Diseases 40 (3): 308-311
266. Kadivar MR, Ghaneh-Shirazi R, Khavandegaran F, Karimi M. Epidemiology of tuberculosis among Afghan immigrants in Fars province, Southern Islamic Republic of Iran. East Mediter Health J. 2007 Jul-Aug; 13(4):758-64.
267. Karimi M, Nikrooz P, Kashef S, Jamalian N, Davatolagh Z. RBC alloimmunization in blood transfusion dependent beta-thalassemia patients in Southern Iran. Int J Lab Hematol. 2007 Oct; 29(5):321-6
268. Afrasiabi A, Lecchi A, Artoni A, Karimi M, Ashouri E, Peyvandi F, Mannucci PM. Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran. Platelets. 2007 Sep; 18(6):409-13
269. Karimi M, Khanlari M, Rachmilewitz EA. Cerebrovascular accident in beta-thalassemia major (beta-TM) and beta-thalassemia intermedia (beta-TI). 2008; American Journal of Hematology 83 (1): 77-79

270. Bazrgar M, Karimi M, Fathzadeh M, Senemar S, Peiravian F, Shojaee A, Saadat M. Apolipoprotein E polymorphism in Southern Iran: E4 allele in the lowest reported amounts. *Mol Biol Rep.* 2008; 35 (4): 495-499
271. Karimi M. Bone mineral density and thalassemia-reply. *Indian Pediatr.* 2007 Jul; 44(7):550
272. Karimi M, Borhani Haghghi A, Raisi H, Yazdani M, Namazi MR. Is β -thalassemia trait a protective factor against ischemic cerebrovascular attacks? *Scientific Medical Journal.* Ahwaz Jundishapur University of Medical Sciences. Winter 2007;51 (4-5):753-756
273. Sabzi A, Karimi M. A 13-year study on the prevalence and clinical features of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in patients referring hospitals to Shiraz University. *Scientific Medical Journal.* Ahwaz Jundishapur University of Medical Sciences. 2007 Spring; 52(1-6):16-24
274. Akbari A, Imanieh MH, Karimi M, Tabatabaee HR. Hepatitis C virus antibody positive cases in multitransfused thalassemic patients in South of Iran. *Hepatitis Monthly* 2007; 7(2): 63-66
275. Karimi M, Hashemi A, Ghiam AF, Jahromi SS, Toobaee S. Substance dependency in Iranian patients with hemophilia. *Addict Behav.* 2007 Feb; 32(2):365-9
276. Karimi M, Rahmani S, Ardestiri R, Rahman Attar A, Pasalar M. Cost of care in Iranian hemophilic patients. *IRCMJ,* 2007; 9(3):1561-4395
277. Bazrgar M, Karimi M, Peiravian F, Fathzadeh M, Fattah MJ. Apolipoprotein E4 allele and the risk of left ventricular dysfunction in thalassemia major. *Iranian Cardiovascular Research Center.* 2007; 1(1):13-19
278. Foroughinia F, Karimi M. The protective effects of ginkgo biloba extract in decreasing hemolysis of RBC in glucose-6-phosphate dehydrogenase-deficient patients. *J Pediatr Hematol Oncol.* 2007 Jul; 29(7):511-512
279. Karimi M, Jamalian N, Rasekhi A, Kashef S. Magnetic resonance imaging (MRI) findings of joints in young β -thalassemia major patients. Fluid surrounding the scaphoid bone. *J Pediatr Hematol Oncol* 2007 June; 29(6):393-8
280. Monaldini L, Assetta R, Duga S, Peyvandi F, Karimi M, Malcovati M, Tenchini ML. Mutational screening of six afibrinogenemic patients: identification and characterization of four novel molecular defects. *Thromb Haemost.* 2007 Apr;97(4):546-51
281. Bazrgar M, Karimi M, Peiravian F, Fathzadeh M. Apolipoprotein E gene polymorphism and left ventricular function in Iranian patients with thalassemia major. *Haematologica.* 2007 Feb;92(2):256-7
282. Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S. Bone mineral density in beta-thalassemia major and intermedia. *Indian Pediatr.* 2007 Jan;44(1):29-32
283. Karimi M, Jamalian N, Yarmohammadi H, Askarnejad A, Afrasiabi A, Hashemi A. Premarital screening for β -thalassemia in southern Iran: options for improving the programme. *J Med Screen* 2007; 14: 62-66
284. Karimi M, Yarmohammadi H, Cappellini MD. Analysis of intelligence quotient in patients with homozygous beta-thalassemia. *Saudi Med J.* 2006 Jul; 27(7): 982-5
285. Yavarian M, Farshidfar GR, Karimi M, Almoazzez M, Harteveld CL, Giordano PC. Survival analysis of transfusion dependent β -thalassemia major patients. *J Res Health Sci.* 2006; 6(2):8-13

286. Karimi M, Zekavat OR, Sharifzadeh S, Mosavizadeh K. Clinical response of patients with sickle cell anemia to cromolyn sodium nasal spray. *Am J Hematol.* 2006 Aug; 291(1):35-9.
287. Karimi M, Sabzi A, Peyvandi F, Mannucci P.M. Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in Southern Iran. *Intern Emerg Med.* 2006;1(1):35-39
288. Marvasti VE, Dastoori P, Karimi M. Is beta-thalassemia trait a risk factor for developing depression in young adults? *Ann Hematol.* 2006 Dec; 85(12):873-4
289. Shahian M, Zekavat O, Karimi M. Extensive thrombosis following central venous catheterization in a neonate with homozygous protein C deficiency presenting purpura fulminans. *Care Rep Clin Pract Rev.* 2006;7: 107-110
290. Karamifar H, Karimi M, Amirkhani GH, Badiei M. Endocrine function in thalassemia intermedia. *IJBS* Vol 2, No 3, September 2006: 236-240
291. Nabavizadeh S.H, Karimi M, Amin R. Cutaneous finding in anti thymocyte globulin induced serum sickness. *Iran J Allergy Asthma Immunol.* 2006 March;5(1):39-40
292. Pishva N, Karimi M. A pilot study on the rate of hemoglobinopathies in hyperbilirubinemic term neonates at Nemazee hospital Shiraz, Iran. *Journal of Shaheed Sadoughi University of Medical Sciences and Health Services.* Winter 2006;13(5):15-18
293. Bazrgar M, Karimi M. Frequency of apolipoprotein E alleles in Iranian populations. *Iranian journal of biotechnology*, Vol. 4, No. 2, April 2006: 141
294. Imanieh MH, Mowla A, Zohouri D, Forootan HR, Karimi M. Spontaneous perforation of the common bile duct with eosinophilia in an 18-month-old girl: A case report and review of literature. *Med Sci Monit.* 2006 Mar;12(4):31-33
295. Karimi M, Sabzi A, Peyvandi E, Mannucci PM. Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran. *J Thromb Haemost.* 2006 Mar;4(3):701-2
296. Karimi M, Garagiola M.B, Sharif Kazemi S., et al. Molecular study of vascular endothelial growth factor gene in Iranian patients after myocardial infarction. *IJMS.* 2006 March; 31(1): 1-4
297. Kashef MA, Kashef S, Handjani F, Karimi M. Hodgkin lymphoma developing in a 4.5 year-old girl with hyper-IgE syndrome. *Pediatr Hematol Oncol.* 2006 Jan-Feb; 23(1):59-63
298. Karimi M, Marvasti VE, Motazedian S, Sharifian M. Is beta-thalassemia trait a protective factor against hypertension in young adults? *Ann Hematol.* 2006 Jan; 85(1): 29-31.
299. Karimi M, Panahande A, Afrasiabi A. Evaluation of factor V leiden and prothrombin mutations in South of Iran. *ARMAGHANDANESH.* Winter 2006; 11(4):81-88.
300. Amin A, Jalali S, Amin R, Aale-yasin S, Jamalian N, Karimi M. Evaluation of the serum levels of immunoglobulin and complement factors in β -thalassemia major patients in Southern Iran. *Iranian Journal of Immunology.* 2005;2(4): 221-226
301. Karimi M, Imanieh MH, Ghiam A, Hashemi Z. Investigation of helicobacter pylori infection in β -thalassemia major patients with recurrent abdominal pain. *European Journal of Gastroenterology & Hepatology.* 2005 Dec.; 17(12):1363-7.
302. Afrasiabi A, Artoni A, Karimi M, Peygandi F, et al. Glanzmann thrombasthenia and Bernard-Soulier syndrome in South Iran. *Clin Lab Hematol.* 2005 Oct; 27(5):324-7.
303. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. *J Pediatr Hematol Oncol.* 2005 Jul;27(7):380-5

304. Yavarian M, Karimi M, Zorai A, et al. Molecular basis of Hb H disease in southwest Iran. *Hemoglobin*. 2005; 29(1): 43-50
305. Momen T, Karimi M, Haghigat H. Role of helicobacter pylori infection in sickle cell disease with recurrent abdominal pain. *Armaghane-danesh*. 2005 Autumn; 10(3): 35-40
306. Asadipooya A, Karamizadeh Z, Bagheri MH, Rasekhi A, Karimi M, et al. Radiologic findings of childhood acute lymphoblastic leukemia during and after chemotherapy. *Ahwaz Jundishapur University of Medical Sciences*. Summer 2005; 4(2): 123-126
307. Geramizadeh B, Daneshbood Y, Karimi M. Cytology of brain metastasis of yolk sac tumor. *Acta Cytol*. 2005 Jan-Feb; 49(1):110-1
308. Yavarian M, Sharifi S, Harteveld Cl, Giordano PC, Karimi M. The haemoglobin O-Indonesia in South of Iran: a case report and review of literature. *Haema* 2005; 8(1): 129-132
309. Mowla A, Karimi M, Afrasiabi A, De Sanctis V. Prevalence of diabetes mellitus and impaired glucose tolerance in beta thalassemia patients with and without hepatitis C virus infection. *Pediatric Endocrinology Reviews (Supplement)*. 2004 Dec; 2(2):282-4.
310. Karamifar H, Karimi M, Amirhakimi GH, et al. Reduced insulin growth factor I concentrations in iron-overloaded β thalassemic patients with normal growth hormone secretion and liver function. *Pediatric Endocrinology Reviews (Supplement)*. 2004 Dec;2(2): 256-8.
311. Karimi M, Yavarian M, Delbini P, et al. Spectrum and haplotypes of the HFE hemochromatosis gene in Iran: H63D in beta-thalassemia major and the first E277K homozygous. *Hematol J*. 2004;5(6):524-7.
312. Enayat MS, Karimi M, Chana G, et al. Mutation analysis in f9 gene of 17 families with haemophilia B fror Iran. *Haemophilia*. 2004 Nov; 10(6): 751-5.
313. Castelli R, Graziadei G, Karimi M, et al. Intrathoracic masses due to extramedullary hematopoiesis. *Am J Med Sci*. 2004 Nov; 328(5):299-303.
314. Karimi M, Karamifar H. Short stature in Beta thalassemia minor subjects in Iran. *Med Sci Monit*. 2004 Oct 26; 10(11): 603-605.
315. Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. *Haematologica*. 2004 Oct; 89(10): 1172-8.
316. Karimi M, Zakerinia M, Khojasteh HN, Ramzi M, et al. Successful treatment of recombinant factor VIIa in hemorrhagic cystitis induced by cyclophosphamide in post bone marrow transplantation. *J Thromb Haemost*. 2004 Oct; 2(10): 1853-5.
317. Bazrgar M, Peiravian F, Karimi M, Fathzadeh M. Correlation between left ventricular dysfunction with hematological parameters and Iron chelation in β -thalassemia major. *JMR*. Autumn 2004; 3(1): 48-58
318. Menegatti M, Karimi M, Garagiola I, Mannucci P, et al. A rare inherited coagulation disorder: Combined homozygous factor VII and factor X deficiency. *Am J Hematol*. 2004 Sep; 77(1): 90-1.
319. Karimi M, Peyvandi F, Siboni S, Ardestiri R, Gringeri A, Mannucci PM. Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy. *Haemophilia*. 2004 Jul; 10(4):367-9.
320. Alborzi A, Cheriki S, Karimi M, Kalani M, Aboodi B. Survey incidence rate of bacterial infection in febrile neutropenic patient (under 15) admitted in Shiraz Medical Hospital (1379-1380). *Iranian Journal of Infectious Diseases and Tropical Medicine*. 2004; 9(24):6-9.

321. Asadi-pooya AA, Karimi M, Imanieh MH. Growth retardation in children with thalassemia major. *Haema* 2004; 7(4): 493-496.
322. Alavi M, Nabavizadeh A, Mowla A, Karimi M. Bone scintigraphy in acute lymphoblastic leukemia. *IJMS*. 2004 June; 29(2), 14-16.
323. Karimi M, Mosallanejad L, Abdolahifard M. Liver enzyme assessment in thalassemia major patients who underwent bone marrow transplantation, Shiraz 2002. *JMR*. Spring 2004; 2(3): 62-70
324. Peyvandi F, Tagliabue L, Menegatti M, Karimi M, Komaromi I, Katona E, Muszbek L, Mannucci PM. Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency. *Hum Mutat*. 2004 Jan; 23(1):98.
325. Asadipooya S, Karamizadeh Z, Rahiminejad MR, Shahriari M, Karimi M. Calcium metabolism disorders in childhood acute lymphoblastic lymphoma, before and after chemotherapy. *Iranian Journal of Endocrine and metabolism*. 2003; 5(2):211-214.
326. Pasalar M, Mojarrab M, Rasekhi AR, Afrasiabi A, Yazdanpanah F, Karimi M. Childhood Neuroblastoma: A 10-Years Study (1991-2001). *Journal of Medical Research*. 2003; 1(4):25-33.
327. Rahimi Z, Karimi M, Haghshenass M, Merat M. β -Globin gene cluster haplotypes in sickle cell patients from Southwest Iran. *American Journal of Hematology*. 2003;74:156-160
328. Karimi M, Habibzadeh F, De Sanctis V. Hypoparathyroidism with extensive intracerebral calcification in patients with beta-thalassemia major. *J Pediatr Endocrinol Metab* 2003 Jul-Aug; 16 (6): 883-6
329. Karimi M, Yarmohammadi H. Seasonal variation in the onset of childhood leukemia /lymphoma, 1996 to March 2000, Shiraz, Iran. *Hematol Oncol*. 2003 Jun; 21 (2):51-5
330. Mannucci PM, Karimi M, Mosalaei A, Canciani MT, Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). *Haematologica*. 2003 Apr; 88(4): 454-8
331. Karimi M, Martinez Di Montemuros F, Danielli MG, Farjadian S, Afrasiabi A, Fiorelli G, Cappellini MD. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Fars province of Iran. *Haematologica*, 2003 Mar; 88(3): 346-7.
332. Kadivar MR, Yarmohammadi H, Mirahmadizadeh AR, Vakili M, Karimi M. Prevalence of iron deficiency anemia in 6 months to 5 years old children in Southern Iran. *Med Sci Monit*. 2003 Feb; 9(2): 100-4.
333. Karimi M, Yarmohammadi H, Sabri MR. An analysis of prognostic factors and the five-year survival rate in children with lymphoblastic leukemia. *Med Sci Monit*. 2002 Dec; 8(12): 792-6.
334. Payvandi F, Spreafico M, Karimi M, Zeinali S, Mannucch PM. Allele frequency of CYP2C9 polymorphisms in Iran. *Thromb Haemost* 2002;88:874-5
335. Karimi M, Rasekhi AR. Efficiency of premarital screening of beta- thalassemia trait using MCH rather than MCV in the population of Fars Province, Iran. *Haematologia (Budap)* 2002;32(2):129-33
336. Karimi M, Yarmohammadi H, Ardestiri R. Inherited coagulation disorders in Southern Iran. *Haemophilia* 2002 Nov; 8(6):740-4
337. Kumar PV, Karimi M, Monabbati A, et al.: Cytology of leukemic lymphadenopathy. *Acta Cytol* 2002 Sep-Oct;46(5):801-7

338. Karimi A, Nategian A, Karimi M, Shirvani B. Correlation between acute phase inflammation markers with cardiac complications in patients with Kawasaki disease. Journal of Hamedan University of Medical Sciences. Autumn 2002; 9(3): 17-21
339. Karimi M, Asadipooya A, Khademi B, et al: Evaluation of the incidence of sensory – neural hearing loss in Beta – thalassemia major patients under regular chelation therapy with desferrioxamine. Acta Haematol. 2002; 108(2):79-83.
340. Karimi M, Yarmohammadi H, Ghavanini A, Kumar P. Epidemiological surveillance of pediatric Hodgkin's disease in Southern Iran. Med Sci Monit. 2002 Aug;8(8):572-5
341. Kumar PV, Moosavi A, Karimi M, Bedayat GR: Fine needle aspiration of Langerhans cell histiocytosis of the lymph nodes. A report of six cases. Acta Cytol. 2002 Jul-Aug;46(4):753-6
342. Karimi M, Yarmohammadi H, Zeinali S, et al: Beta thalassemia intermedia from Southern Iran: IVS- II- I (G→ A) is the prevalent thalassemia intermedia Allele. Hemoglobin 2002 May;26(2):147-54
343. Karimi M, Kadivar R, Yarmohammadi H. Assessment of the prevalence of iron deficiency anemia, by serum ferritin, in pregnant women of Southern Iran. Med Sci Monit 2002 Jul;8(7):488-92
344. Karimi M, Ghavanini AA. Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus antibodies among multitransfused children in Shiraz – Iran. J Pediatr Child Health 2001 Dec;37(6):564-6
345. Karimi M, Ghavanini AA: Seroprevalence of HBsAg, anti-HCV, and anti-HIV Among haemophiliac patients in Shiraz, Iran. Haematologica (Budap). 2001; 31(3): 251 – 5
346. Kumar PV, Moosavi A, Karimi M, et al.: Subclassification of Localized leishmania lymphadenitis in FNA smears. Acta Cytologica, 2001 Jul - Aug; 45 (4): 547 – 54
347. Karimi M, Ghavanini AA, Kadivar MR: Regional mapping of the gene frequency of β-thalassemia in Fars Province, Iran during 1997 – 1998. Irn J Med Sci 2000; 25 (3&4): 134 – 137
348. Pedram M, Zandian KM, Kiekhaie B, Mosawai F and Karimi M: Children clinical oncology emergency with 14 case reports of vincava and mediastinum syndromes in Ahwaz. Scientific Med J Ahwaz Univ Med Sci 1998; 23: 69 – 83